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Abstract 
 
Hepatitis C virus (HCV), a positive single stranded RNA (ssRNA) virus that replicates in 
the liver, infects 200 million people worldwide, with approximately 80% of infected 
individuals ultimately suffering from chronic HCV infection. Antiviral therapies, 
including interferon and ribavirin, have improved considerably in recent years, but are 
effective in only about one-half of those treated, and are associated with significant side 
effects and toxicity.  
Innate immune defenses are essential to control viral infection; the innate response is 
activated through recognition of viral macromolecular motifs known as pathogen-
associated molecular patterns (PAMPs) that are recognized by a multitude of Pathogen 
recognition receptors (PRRs). Although immune activation induced by HCV RNA or 
proteins has been extensively studied, the detection of HCV by the innate immune system 
remains poorly understood. Despite activation of the immune response early after HCV 
infection in vivo, the persistent increase inpatient HCV viral load suggests the failure of 
the immune response to control HCV infection. A better understanding of the 
mechanisms of immune activation induced by HCV is crucial for development of 
effective strategies for HCV treatment. 
Here we demonstrate in primary cell models that the HCV genome contained GU-rich 
RNA sequences that specifically trigger Toll-like receptors (TLR) 7/8, resulting in 
maturation of plasmacytoid dendritic cells (pDCs) and production of type I interferon 
(IFN), induction of inflammatory cytokines and chemokines in different antigen 
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presenting cells (APCs). Cytokines produced by monocytes and pDCs upon stimulation 
of HCV-derived ssRNA inhibited HCV production in an IFN-dependent manner, whereas 
cytokines produced by myeloid DCs (mDCs) and macrophages had no inhibitory effect 
on virus production, due to a defect in IFN induction by HCV ssRNA in these cells.  
TLR7/8 stimulated cytokines also down-regulated the expression of the HCV receptor 
CD81 on Huh7.5 in an IFN-independent manner that may restrict HCV infection. 
However, although HCV receptors like CD81 were widely expressed on different subsets 
of lymphocytes, DCs and monocytes did not respond to HCV particles, and our data 
indicates that only macrophages sense HCV and produce inflammatory cytokines. The 
recognition of HCV by macrophages is related to the expression of DC-SIGN on 
macrophages, and results in TLR7/8 engagement. Similar to a TLR7/8 agonist, HCV 
stimulation induces inflammatory cytokine production (TNF-α, IL-8, IL-6 and IL-1b) by 
macrophages but does not stimulate interferon-beta production in macrophages, 
Congruously, TLR7/8 and HCV RNA mediated cytokine production in macrophages did 
not inhibit HCV replication.  
Our results reveal that HCV RNA has the potential to trigger TLR7/8 in DC populations, 
and initiate an innate immune response against HCV infection that leads to an IFN-
dependent suppression of viral replication. However, HCV is able to escape detection by 
monocytes and DCs, which produce type I IFN and suppress HCV replication when 
TLR7/8 is engaged. Macrophages possess the capacity to detect HCV, in part because of 
surface expression of DC-SIGN. In turn, macrophages produce inflammatory cytokines 
that nevertheless fail to inhibit HCV replication due to lack of IFN-beta production. 
Evasion of antiviral defense by HCV may explain the failure of innate immunity in 
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control of HCV infection. Moreover, inflammatory cytokine production by macrophages 
upon HCV stimulation in vitro suggests that activation of macrophages may contribute to 
inflammation in HCV infected individuals.  
 
Key words: Hepatitis C virus, dendritic cells, interferon, single-strand RNA, TLR7, 
TLR8, CD81, DC-SIGN, macrophages 
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Résumé 
 
 
Le virus de l’hépatite C (VHC) est un virus à ARN simple brin positif (ssARN) qui se 
replique dans le foie. Deux cents millions de personnes sont infectées par le virus dans le 
monde et environ 80% d’entre elles progresseront vers un stade chronique de l’infection. 
Les thérapies anti-virales actuelles comme l’interféron (IFN) ou la ribavirin sont de plus 
en plus utilisées mais ne sont efficaces que dans la moitié des individus traités et sont 
souvent accompagnées d’une toxicité ou d’effets secondaires indésirables.  
Le système immunitaire inné est essentiel au contrôle des infections virales. Les réponses 
immunitaires innées sont activées suite à la reconnaissance par les Pathogen Recognition 
Receptors (PRRs), de motifs macromoléculaires dérivés du virus appelés Pathogen-
Associated Molecular Patterns (PAMPs). Bien que l'activation du système immunitaire 
par l'ARN ou les protéines du VHC ait été largement étudiée, très peu de choses sont 
actuellement connues concernant la détection du virus par le système immunitaire inné. 
Et même si l’on peut très rapidement déceler des réponses immunes in vivo après 
infection par le VHC, l’augmentation progressive et continue de la charge virale met en 
évidence une incapacité du système immunitaire à contrôler l’infection virale. Une 
meilleure compréhension des mécanismes d’activation du système immunitaire par le 
VHC semble, par conséquent, essentielle au développement de stratégies antivirales plus 
efficaces. 
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Dans le présent travail nous montrons, dans un modèle de cellule primaire, que le génome 
ARN du VHC contient des séquences riches en GU capables de stimuler spécifiquement 
les récepteurs de type Toll (TLR) 7 et 8. Cette stimulation a pour conséquence la 
maturation des cellules dendritiques plasmacytoïdes (pDCs), le production d’interféron 
de type I (IFN) ainsi que l’induction de chémokines et cytokines inflammatoires par les 
différentes types de cellules présentatrices d’antigènes (APCs). Les cytokines produites 
après stimulation de monocytes ou de pDCs par ces séquences ssARN virales, inhibent la 
production du virus de façon dépendante de l’IFN. En revanche, les cytokines produites 
après stimulation de cellules dendritiques myéloïdes (mDCs) ou de macrophages par ces 
mêmes séquences n’ont pas d’effet inhibiteur sur la production virale car les séquences 
ssARN virales n’induisent pas la production d’IFN par ces cellules.   
Les cytokines produites après stimulation des TLR 7/8 ont également pour effet de 
diminuer, de façon indépendante de l’IFN, l’expression du récepteur au VHC (CD81) sur 
la lignée cellulaire Huh7.5, ce qui pourrait avoir pour conséquence de restreindre 
l’infection par le VHC. Quoiqu’il en soit, même si les récepteurs au VHC comme le 
CD81 sont largement exprimés à la surface de différentes sous populations 
lymphocytaires, les DCs et les monocytes ne répondent pas aux VHC, Nos résultats 
indiquent que seuls les macrophages sont capables de reconnaître le VHC et de produire 
des cytokines inflammatoires en réponse à ce dernier. La reconnaissance du VHC par les 
macrophages est liée à l’expression membranaire de DC-SIGN et l’engagement des TLR 
7/8 qui en résulte. Comme d’autres agonistes du TLR 7/8, le VHC stimule la production 
de cytokines inflammatoires (TNF-α, IL-8, IL-6 et IL-1b) mais n’induit pas la production 
d’interféron-beta par les macrophages. De manière attendue, la production de cytokines 
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par des macrophages stimulés par les ligands du TLR 7/8 ou les séquences ssARN virales 
n’inhibent pas la réplication virale. 
Nos résultats mettent en évidence la capacité des séquences ssARN dérivées du VHC à 
stimuler les TLR 7/8 dans différentes populations de DC et à initier une réponse 
immunitaire innée qui aboutit à la suppression de la réplication virale de façon 
dépendante de l’IFN. Quoiqu’il en soit, le VHC est capable d’échapper à sa 
reconnaissance par les monocytes et les DCs qui ont le potentiel pour produire de l’IFN et 
inhiber la réplication virale après engagement des TLR 7/8. Les macrophages possèdent 
quant à eux la capacité de reconnaître le VHC grâce en partie à l’expression de DC-SIGN 
à leur surface, mais n’inhibent pas la réplication du virus car ils ne produisent pas d’IFN. 
L’échappement du VHC aux défenses antivirales pourrait ainsi expliquer l’échec du 
système immunitaire inné à contrôler l’infection par le VHC. De plus, la production de 
cytokines inflammatoires observée après stimulation in vitro des macrophages par le 
VHC suggère leur potentielle contribution dans l’inflammation que l’on retrouve chez les 
individus infectés par le VHC. 
 
Mots clefs: virus de l’hépatite C, cellules dendritiques, interféron, ARN simple brin, 
TLR7, TLR8, CD81, DC-SIGN, macrophages 
VIII 
 
Table of Contents 
 
ABSTRACT ................................................................................................................... II 
RÉSUMÉ ....................................................................................................................... V 
TABLE OF CONTENTS ........................................................................................... VIII 
LIST OF FIGURES ...................................................................................................... XI 
CONTRIBUTION OF AUTHORS ............................................................................. XII 
ABBREVIATIONS ................................................................................................... XIV 
ACKNOWLEDGEMENTS ....................................................................................... XVI 
CHAPTER 1 ................................................................................................................... 1 
INTRODUCTION .......................................................................................................... 1 
1. Hepatitis C virus- prevalence ................................................................................... 2 
2. Discovery of HCV ................................................................................................... 4 
3. HCV virology .......................................................................................................... 5 
3.1 HCV genome and proteins 6 
3.2 Viral life cycle 9 
4. Infectious HCV culture system in vitro ................................................................. 10 
5. HCV treatments and limitations ............................................................................ 12 
6. Acute, chronic infection and viral clearance ......................................................... 17 
7. Immune response and HCV infection .................................................................... 19 
7.1 Innate immunity 20 
7.2 Adaptive immunity 21 
8. TLR7 and TLR8 ..................................................................................................... 23 
9. Role of TLR7 in immune response against HCV infection ................................... 26 
IX 
 
10. HCV detection by antigen-presenting cells ........................................................... 27 
HYPOTHESIS AND OBJECTIVES ............................................................................ 30 
CHAPTER 2 ................................................................................................................. 32 
HCV derived ssRNA induce innate immune response against HCV infection via 
TLR7 and TLR8 ............................................................................................................ 32 
Abstract ....................................................................................................................... 34 
Results ......................................................................................................................... 37 
1. Identification of ssRNA sequences in HCV genome that stimulate innate 
immune responses 37 
2. Specific recognition of HCV-derived ssRNA by TLR7 and TLR8 38 
3. Cytokine production and DC maturation upon ssRNA stimulation 39 
4. Effect of HCV-derived ssRNA-induced cytokines on HCV infection 40 
5. HCV-derived ssRNA-mediated cytokines down-regulate CD81 
expression on huh7.5 41 
6. HCV-derived ssRNA pretreatment impairs pDCs capacity to produce 
IFNα 42 
Discussion ................................................................................................................... 44 
Materials and methods ................................................................................................. 49 
Reference ..................................................................................................................... 73 
CHAPTER 3 ................................................................................................................. 76 
Macrophages sense Hepatitis C virus to initiate innate immunity ................................ 76 
Abstract ....................................................................................................................... 78 
Results ......................................................................................................................... 83 
1. Macrophages but not monocytes and DCs sense HCVcc 83 
X 
 
2. Induction of inflammatory cytokines by HCVcc stimulation 84 
3. HCVcc as well as TLR7/8 agonist do not trigger interferon pathway in 
macrophages 84 
4. Antiviral activity and responsiveness to HCVcc 85 
5. RNA sensors involved in HCV recognition 86 
6. DC-SIGN expression and responsiveness to HCV 87 
7. Difference in responsivenss of DC-SIGN expressing cells to HCV 88 
Discussion ................................................................................................................... 90 
Materials and methods ................................................................................................. 94 
Reference ................................................................................................................... 112 
CHAPTER 4 ............................................................................................................... 115 
DISCUSSION ............................................................................................................. 115 
1. Summary of findings ........................................................................................... 116 
2. Immunogenicity of HCV ..................................................................................... 117 
3. TLR7 and innate immunity against HCV infection ............................................. 119 
4. Induction of innate immune response and inflammation in HCV infection ........ 121 
5. Detection of HCV by antigen-presenting cells .................................................... 123 
6. Interferon and control of HCV infection ............................................................. 126 
Perspectives ................................................................................................................. 130 
APPENDIX : JOURNAL PUBLICATIONS .............................................................. 178 
 
 
 
XI 
 
LIST OF FIGURES 
 
Chapter 1 
Figure 1. Geographic distribution of Hepatitis C prevalence. ............................................ 3 
Figure 2 Global distribution of HCV genotypes ................................................................. 4 
Figure 3. Genome and proteins of HCV virus. ................................................................... 8 
Figure 4 Hepatitis C virus (HCV) viral cycle and targets for drug development ............. 14 
Chapter 2 
Figure 1 GU-rich sequences in HCV genome induce TNF-α production. ....................... 56 
Figure 2 Specificity of TLR7/8 triggering by HCV derived ssRNA ................................ 58 
Figure 3 Inflammatory cytokines and chemokines production by monocytes, mDCs and 
pDCs. ................................................................................................................................ 60 
Figure 4 Maturation and type I IFN production of pDC ................................................... 63 
Figure 5 HCV-ssRNA mediated cytokines inhibit HCV production in IFN-dependent 
mannar. .............................................................................................................................. 66 
Figure 6 HCV-ssRNA mediated cytokines inhibit HCV production in IFN-dependent 
mannar. .............................................................................................................................. 68 
Figure 7 HCV-derived ssRNA down-regulate CD81 expression on huh7.5. ................... 70 
Figure 8 Impairment of IFN expression in pDC with HCV-derived ssRNA pre-treatment
 ........................................................................................................................................... 72 
Chapter 3 
Figure 1 Macrophages sense HCV . ................................................................................. 98 
Figure 2 Dose-dependent activation and Inflammatory cytokines induction by HCVcc 
stimulation. ...................................................................................................................... 100 
Figure 3 Expression of Interferon and interferon-stimulated genes in macrophage upon 
HCV stimulation. ............................................................................................................ 102 
Figure 4 Antiviral activity and responsiveness to HCV. ................................................ 104 
Figure 5 Pathway involved in HCV recognition. ............................................................ 106 
Figure 6 DC-SIGN mediated uptake of HCV. ................................................................ 109 
Figure 7 Responsiveness of macrophages and MDDCs to HCV. .................................. 111 
XII 
 
 
CONTRIBUTION OF AUTHORS 
 
 
Chapter 2 HCV derived ssRNA induce innate immune response against HCV 
infection via TLR7 and TLR8  
 
Yuwei Zhang, Elias Said, Abdel-Hakeem MS, Zhong He, Francesco A. Procopio, 
Rafick-Pierre Sekaly 
 
Yuwei Zhang and Elias Said defined the criteria of GU-rich sequence and 
selected nine sequences from HCV genome. Yuwei Zhang performed screening 
of RNA sequences and TNF-α ELISA. Yuwei Zhang, with help of Zhong He, 
performed the luciferase assay. Elias Said performed DC separation and 
cytokine/chemokine dectection by Cytometric Bead Array with the help of 
Yuwei Zhang. Francesco A. Procopio optimized the method for HCV 
quantification with the help of Abdel-Hakeem MS. Yuwei Zhang and Zhong He 
performed viral production and infection in vitro. The manuscript and the figures 
were generated by Yuwei Zhang under the supervision of Rafick-Pierre Sekaly. 
 
 
 
XIII 
 
Chapter 3 Macrophages sense Hepatitis C virus to initiate innate immunity 
 
Yuwei Zhang, Elias Said, Zhong He, Francesco A. Procopio, Rafick-Pierre 
Sekaly 
 
Yuwei Zhang performed cell separation and macrophage generation. Yuwei 
Zhang performed TNF-α ELISA. Zhong He performed cytokine/chemokine 
dectection by Cytometric Bead assay. Francesco A. Procopio optimized the 
method for HCV quantification. Yuwei Zhang and Zhong He performed viral 
production and infection in vitro. Yuwei Zhang performed the measurement of 
gene expression and viral quantification by real-time PCR with the help of 
Francesco A. Procopio. Yuwei Zhang performed the phenotypic staining and 
flow cytometric analysis of innate immune cells and macrophages. The 
manuscript and the figures were generated by Yuwei Zhang, in collaboration 
with Elias Said, under the supervision of Rafick-Pierre Sekaly. 
 
 
 
 
 
 
 
XIV 
 
ABBREVIATIONS 
 
APC:             Antigen presenting cell 
ARFP:           Alternate reading frame protein 
CBA:             Cytometric Bead Array 
CLDN1:        Claudin 1 
CTL:              Cytotoxic T lymphocyte 
DC-SIGN:     Dendritic Cell-Specific Intercellular adhesion molecule-3- Grabbing non-integrin 
dsRNA:         Double-strand RNA 
Flu:                Influenza virus 
GM-CSF:      Granulocyte-macrophage colony-stimulating factor 
HCV:            Hepatitis C virus 
HCVcc:         Cell culture-derived HCV 
HCVpp:        HCV pseudotype particles 
HIV:              Human immunodeficiency virus 
HSC:             Hepatic stellate cell 
IFN:              Interferon 
IL-4:             Interleukin 4 
IRES:            Internal ribosome entry site 
IRF-3:           Regulatory factor-3 
ISGs:            Interferon-stimulated genes 
KC:               Kupffer cell 
LDLR:          Low-density lipoprotein receptor 
MDA-5:        Melanoma Differentiation-Associated protein 5 
mDC:            Myeloid dendritic cell 
MDDC:        Monocyte-differentiated DC 
XV 
 
MDM:         Monocytes-derived macrophage 
nAb:            Neutralizing antibody 
NK:             Natural killer cell 
NLP:           Nucleocapsid-like particle 
NS:              Nonstructural protein 
NTR:           Non-translated region 
PAMPs:       pathogen-associated molecular patterns 
PBMC:        peripheral blood mononuclear cell 
pDC:            Plasmacytoid dendritic cell 
PRRs:          Pathogen recognition receptors 
RIG-I:          Retinoic acid-inducible gene-I 
RLH:           RIG-I-like RNA helicase 
SRB1:          Scavenger receptor class B-1 
ssRNA:       Single stranded RNA 
Stat1:          Signal transducer and activator of transcription 1 
SV:              Sendai virus 
SVR:           Sustained antiviral response 
TLR:           Trigger Toll-like receptors 
VLP:           Viral-like particles 
 
 
 
 
 
 
XVI 
 
ACKNOWLEDGEMENTS 
 
 
First of all, I would like to express my sincerest appreciation to my supervisor, Dr. 
Rafick-Pierre Sékaly, who has provided me with the personal and financial resources for 
the completion of this work. With his expertise, extensive knowledge, patience, and 
attention, I have been able to learn and grow professionally. The experiences with him 
have been invaluable in shaping the researcher that I want to be. 
I would like to express my gratitude to Dr. Elias Said for his valuable contribution 
through supervising and the numerous scientific discussions, as well as Dr. Naglaa 
Shoukry for her support. I also would like to thank PhD candidate Mohamed S. Abdel–
Hakeem, Dr. Zhong He and Dr. Mohamed El-Far for their significant help with viral 
production and technical assistance. I also would like to thank Dr. Francesco Procopio for 
his help with optimization of real-time PCR. I also thank Dr. Jeff Ahlers, Dr. Yu Shi, Dr. 
John Hiscott, Dr. Joumana Zeidan and Dr. Petronela Ancuta for their editorial assistance. 
The encouragement and love from my family and friends are very important to me, they 
have support me during my Ph.D. studies. I would not have been able to complete 
without their financial and emotional support.  
  
 
 
 
 
 
 
CHAPTER 1  
 
INTRODUCTION 
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1. Hepatitis C virus- prevalence 
 The hepatitis C virus, also known as HCV, is now a widespread public health 
problem that affects a global audience estimated to be 200 million individuals – equaling 
3.3% of the world’s population. Annually, the number of new reported cases of the 
hepatitis C infection reaches as high as 3 to 4 million (Perz, Armstrong et al. 2006, WHO 
2011). The prevalence of HCV is comparatively lowest in Asia Pacific, Tropical Latin 
America and North America (<1.5%). According to a particular survey, the occurrence of 
HCV antibodies with respect people donating blood averages less than a meager one 
percent for the aforementioned region. On the flip side, the rates are incrementally higher 
as seen in South Asia, Southern Latin America and Europe (1.5%-3%). The occurrence of 
hepatitis C antibodies in Central and East Asia, North Africa/Middle East were reported 
around 3.8% (Mohd Hanafiah, Groeger et al. 2013). As far as many African countries 
were concerned though, alarming rates have been reported, reaching as high as 14.7% in 
Egypt (Mohamoud, Mumtaz et al. 2013). 
HCV infection primarily takes place in the liver and causes hepatitis C (Choo, 
Weiner et al. 1990). The infection is usually asymptomatic in nature (Alberti, Noventa et 
al. 2002, Mendez-Sanchez, Ponciano-Rodriguez et al. 2005), however chronic infection 
can lead to scarring of the liver and subsequently lead to cirrhosis (Freeman, Dore et al. 
2001). Progression of liver disease caused by HCV usually takes decades - As high as 
one-fifth of the people that are infected may go on to develop complications such as liver 
failure, cirrhosis or even hepatocellular carcinoma (Perz, Armstrong et al. 2006). Barring 
hepatocellular carcinoma, with respect to patients that develop cirrhosis or liver cancer, a 
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liver transplant may be required. HCV-induced liver inflammation and cirrhosis is 
considered as one of the major causes for liver transplants (Davis, Albright et al. 2003). 
Only 10% to 40% of HCV-infected individuals can be cured by spontaneous viral 
clearance, and 60% to 90% infected individuals develop chronic infection, depending on 
the genotype of the virus they are contracted (Gerlach, Diepolder et al. 2003, Lehmann, 
Meyer et al. 2004, Micallef, Kaldor et al. 2006). There is no effective vaccine to prevent 
the hepatitis C infection. A combination of peg-interferon and ribavirin is the current 
standard therapy. 
 
 
Figure 1. Geographic distribution of Hepatitis C prevalence 
This image is originally from 
http://commons.wikimedia.org/wiki/File:HCV_prevalence_1999.png 
 
 
4 
 
 
Figure 2. Global distribution of HCV genotypes 
This image is originally from 
http://www.who.int/vaccine_research/documents/ViralCancer7.pdf 
 
2. Discovery of HCV 
In the mid 1970s, a new hepatitis virus was recognized in blood transfusion 
recipients, identified as non-A, non-B hepatitis (Feinstone, Kapikian et al. 1975). A few 
distinctive characteristics aided in separating this new virus from HAV and HBV. 
Infection in chimpanzees produced chronic disease is characterized by inflammation and 
hepatocyte structural changes (Popper, Dienstag et al. 1980, Dienes, Popper et al. 1982). 
Complete identification of the new virus was hindered by difficulties in producing a 
cellular model that allowed viral replication (Lohmann, Korner et al. 1999). In 1987, 
Michael Houghton and Daniel Bradley collaborated to create a molecular cloning 
technique to sequence the viral genome (Choo, Kuo et al. 1989). Once HCV was 
identified, screening for it in blood transfusions became mandatory starting in 1990, 
which subsequently decreased the rate of infection (Kimber 1990, Weiner, Kuo et al. 
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1990). The highest transmission rates were initially from unsanitary injection drug use or 
unsterile needle use such as in unregulated body tattoo art and blood transfusions (Conry-
Cantilena, VanRaden et al. 1996). Occupational exposure to HCV is and has been the 
most difficult type of transmission to control as most infections occur accidentally, even 
with proper precautions observed (Yazdanpanah, De Carli et al. 2005). Since blood 
screening started to be applied, there has been a decrease of HCV infection in developed 
countries. However, transmission of the virus in some areas is still growing despite 
advanced techniques to identify HCV in blood (Alter 2007, Martins, Narciso-Schiavon et 
al. 2011). Owing to the expensive nature of testing for the virus, underdeveloped 
countries are still struggling to control the spread of the virus (van der Poorten, Kenny et 
al. 2008). Still, continued HCV research has led to improved treatments against the virus.  
 
3. HCV virology 
Hepatitis C virus, classified as part of the Flaviviridae family, is predominantly a 
singularly stranded positive-sense RNA virus. This genome is almost 9.6 kilo-bases and 
has six different major genotypes, genotypes 1-6 (Okamoto 1995). HCV has a high 
propensity for genetic variations due to the error-prone nature of the RNA replicase 
(Bukh, Miller et al. 1995, Pawlotsky 1998). Therefore, HCV-infected individuals with 
certain genotypes and subtypes respond atypically to treatment (Manns, McHutchison et 
al. 2001), and the identity of HCV genotypes in infected individuals is important to the 
specific treatment regimen. Throughout the history of HCV therapy, treatment has been 
conventionally less effective—up to 30% to 50%—in patients harboring HCV genotype 1 
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compared to up to 80% effective clearance in genotypes 2 and 3 (Zein, Rakela et al. 1996, 
Neumann, Lam et al. 2000, Lehmann, Meyer et al. 2004). Thus, genotype 1 is associated 
with the development of chronic infection and is also the most prevalent genotype in the 
world (Fig 2). 
 
3.1 HCV genome and proteins 
HCV is a relatively small 50 nm enveloped RNA virus (Kaito, Watanabe et al. 
1994). The genome, flanked by small 5’ and 3’ non-translated regions (NTRs), has one 
open reading frame that translates to a number of proteins of roughly 3000 residues 
(Choo, Richman et al. 1991). The 5’ NTR region is known to contain an internal 
ribosomal entry site, denoted as IRES, and is considered extremely conserved among the 
various genotypes and subtypes. It is essential for RNA translation because it binds the 
40S ribosome subunit, positioning it near the initiation site (Pestova, Shatsky et al. 1998, 
Friebe, Lohmann et al. 2001). The 3’ NTR region with its three domains—6variable 
region, poly U region, and a conserved terminal domain—is highly inconsistent among 
the genotypes (Friebe and Bartenschlager 2002). Areas in the latter two regions are 
required for RNA replication.  
The virus has ten proteins, three of which are structural proteins: core and 
envelope 1 and 2 (Takeuchi, Kubo et al. 1990). In between these non-structural as well as 
structural proteins happens to be a rather small yet integral membrane protein: p7 (Lin, 
Lindenbach et al. 1994). The nonstructural proteins are NS2 and NS3, NS4 (A and B) and 
NS5 (A and B). Barring NS2, the remaining nonstructural proteins are deemed to be an 
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essential requirement for replication (Brenndorfer, Karthe et al. 2009, Morikawa, Lange 
et al. 2011). Extensive research into each of these proteins has revealed specific roles for 
viral replication and survival. Alternatively, a frame shift may occur in the Core protein-
coding region to produce an alternate reading frame protein (ARFP) (Branch, Stump et al. 
2005).  
The hepatitis C core protein is an RNA binding protein that is highly conserved in 
nature (Bukh, Purcell et al. 1994, Hitomi, McDonnell et al. 1995). They are also 
presumed to form the viral capsid. When expressed in several in vitro systems, the 
hepatitis C core protein is known to participate in the formation of NLPs. (Baumert, Ito et 
al. 1998, Blanchard, Brand et al. 2002). The two envelope glycoproteins, that are namely 
E1 and E2, are essential for viral entry and fusion (Bartosch, Dubuisson et al. 2003, 
Nielsen, Bassendine et al. 2004). E2 plays an important role during early stages of the 
infection. E2 interaction with either one or multiple receptor complex components is 
considered to be the root cause behind the initiation of viral attachment (Rosa, 
Campagnoli et al. 1996, Flint and McKeating 2000). p7 is predominantly a small, 63aa 
polypeptide, which is understood to be a fundamental membrane protein (Carrere-
Kremer, Montpellier-Pala et al. 2002, Sakai, Claire et al. 2003).p7 appears to be essential 
for HCV infectivity (Sakai, Claire et al. 2003). NS2, along with the amino-terminal of the 
NS3 protein, along with the NS2-3 protease, splits the NS2 and NS3 (Grakoui, McCourt 
et al. 1993). NS3 is deemed to be a viral protein exhibiting multiple functionalities. NS4A 
plays a supporting role during the NS3 protease activity. NS3-4A has also been seen to 
exhibit added properties while interacting with the pathways of host cells as well as 
proteins, and resultantly may be considered as a vital factor during the lifecycle and 
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pathogenesis of infection (Bartenschlager, Lohmann et al. 1995, Lin, Thomson et al. 
1995). 
 
 
Figure 3. Genome and proteins of HCV virus 
The 9.6 kb positive-strand RNA genome can be schematically depicted at the upper side 
of the figure. The RNA arrangements at the 5’ and 3’ ends of the hepatitis C genome are 
important inputs for translation and replication. The IRES-mediated translation produces a poly-
protein precursor of almost 3000 amino acids. The host and viral proteases split poly-protein 
during and after translation to subsequently result in the 10 proteins depicted here. Adjacent to the 
colored boxes the representation of the known functionality of each protein is depicted. The 
translational frames shift may result in the production ARFP.  
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3.2 Viral life cycle 
HCV infects and replicates in human hepatocytes. Chimpanzees are the only other 
animal model that will sustain replication (Bukh 2004). The HCV life cycle consists of 
five distinct steps: entry, protein translation, RNA replication, virion assembly, and virion 
release. The viral infection starts by binding of the envelope proteins to several host 
cellular receptors: CD81 (Pileri, Uematsu et al. 1998, Cormier, Tsamis et al. 2004), 
scavenger receptor class B-1 (SRB1) (Bartosch, Vitelli et al. 2003), glycosaminoglycans 
(Olenina, Kuzmina et al. 2005), low-density lipoprotein receptor (LDLR) (Monazahian, 
Bohme et al. 1999), and claudin-1 (Evans, von Hahn et al. 2007). But Albecka A et al 
showed recently that LDLR is not essential for infectious HCV particle entry (Albecka, 
Belouzard et al. 2011). Endocytosis of the virion occurs by clathrin mediation and 
acidification of the endosomal compartment (Blanchard, Belouzard et al. 2006). After 
entry, the viral and endosomal membrane fuse, allowing for the release of hepatitis C 
RNA into the cytoplasm. The translation of the viral polyprotein is dependent on the 5’ 
NTR IRES of the positive single-stranded hepatitis C RNA (Otto and Puglisi 2004). The 
proteins—core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B—are manufactured 
in the cytoplasm and localized to the endoplasmic reticulum membrane where HCV 
negative-sense strand RNA production occurs (Liu, Aizaki et al. 2012). In the cytoplasm, 
while HCV proteins are translated from RNA, the proteins may interact with host factors 
to ensure viral survival. HCV proteins, in particular NS4B, mediate the formation of 
membranous webs postulated to be partial ER membranes, where further RNA 
replication from negative strand to positive strand occurs (Elazar, Liu et al. 2004). Close 
to the membranous webs, the RNA and structural proteins assemble into viral particles, 
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which bud into the ER or similar membrane compartments to exocytose out of the cell, 
leaving it intact (Bartenschlager, Penin et al. 2010, Lindenbach and Rice 2013). 
 
4. Infectious HCV culture system in vitro 
It has been very difficult to observe a complete infection cycle of HCV in vitro 
due to the absence of a hepatitis C clone with robust replication and cell line that is 
permissive for HCV infection. HCV replicon (self-replicating sub-genome with selection 
transfected into hepatoma cell lines) was able to provide significant insights regarding the 
functionality of viral RNA and proteins in infection (Lohmann, Korner et al. 1999, 
Blight, Kolykhalov et al. 2000). Replicon-based systems have been broadly used for the 
selection of anti-HCV drugs. Pseudo particles decorated with the HCV envelope GPs 
(HCVpp) allowed the study of steps in viral entry. However, the assembling and the 
release of infectious hepatitis C were not effectively summarized and restated by these 
experimental systems. Many attempts have already been made in the direction of 
developing a proper system for hepatitis C infection and replication in terms of a cell 
culture, however, as far as reports about the latter were concerned, the results were far 
from efficient. Fortunately, this situation took a change for the better with the 
establishment of a new, efficient culture model for hepatitis C infection. The infectious 
HCV system provides an important tool to study HCV infection, anti-HCV drug 
selection, and even HCV-related immune response. The first robust infectious clone, 
JFH1 strain, was isolated from a HCV host. Transfection of in vitro recorded full length 
JFH1 HCV RNA into Huh7 cells was able to replicate efficiently JFH-1 RNA along with 
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the secreting recombinant viral particles into the culture medium (Wakita, Pietschmann et 
al. 2005, Zhong, Gastaminza et al. 2005, Bukh and Purcell 2006). Significantly, the 
secreted viral particles were deemed to be infectious in the case of cultured cells and 
chimpanzees (Kato, Matsumura et al. 2007). It was also reported that cell culture-adapted 
mutations in JFH1 yield higher titers of infectious particles (Liu, Xiao et al. 2012). To 
expand the scope of this novel HCV infection system, several groups have constructed 
chimeric HCV genomes comprising JFH1-derived replicase proteins and structural 
proteins from heterologous HCV strains or other virus (Kylefjord, Danielsson et al. 2013, 
Li, Zhu et al. 2013, Lu, Tao et al. 2013), which might provide a useful tool for virological 
studies and evaluation of antiviral therapies.   
Attempts to propagate HCV in vitro have proven difficult. Developments have led 
to establishment of several systems that support HCV replication in vitro, including 
hepatoma cell lines, primary or immortalized hepatocytes et al (Fournier, Sureau et al. 
1998, Lohmann, Korner et al. 1999, Kanda, Basu et al. 2006, Gondeau, Briolotti et al. 
2013). The rate of infection in the case of cultured cells was comparatively enhanced by 
using permissive cell lines, t but it is still far from perfect due to evidently low yields of 
the virus and minimal spread in cell culture (Sainz, Barretto et al. 2012). Expression of 
essential genes for HCV replication, such as microRNA122, may permit 
efficient HCV RNA replication and infectious virion production in hepatoma cell lines 
(Kambara, Fukuhara et al. 2011, Narbus, Israelow et al. 2011). The most permissive cell 
line for efficient RNA replication in vitro is the human hepatoma cell line Huh-7 and its 
clonal descendants (Blight, McKeating et al. 2002). Huh7.5, a hepatoma cell derived 
from HCV-harboring huh7 clones with prolonged treatment with alpha interferon (IFN-
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alpha) to eliminate self-replicating subgenomic RNA within the cells. Huh7.5 appears 
highly permissive for HCV infection and replication. A single point mutation was 
observed in the dsRNA sensor RIG-I and deemed to positively correlate to seemingly 
increased permissiveness for the replication of HCV RNA (Sumpter, Loo et al. 2005). 
This observation illustrates that lack of antiviral restriction may substantially increase the 
permissiveness for HCV. Furthermore, although hepatocarcinoma cell lines have became 
important new virological tools to study the mechanisms of HCV infection, however, this 
experimental model remains distantly related to physiological and pathological 
conditions. It was reported recently that a new ex vivo model using human adult liver 
slices culture supports efficient replication of primary or culture hepatitis C virus isolates 
(Lagaye, Shen et al. 2012), this provides a powerful tool for studying the viral life cycle 
and dynamics of virus spread in native tissue.  
 
5. HCV treatments and limitations 
HCV therapy has improved considerably since the discovery of the virus in 1989 
(Choo, Kuo et al. 1989). As far as chronic hepatitis C is concerned, the common course 
of treatment is with a glycoprotein commonly known as IFN-alpha, which is integral for 
the treatment since it accents the immune response against the virus (Carithers and 
Emerson 1997). Studies based on a long-term timeframe have suggested that a sustained 
antiviral response (SVR) shows an overall clearance of virus, and is associated with 
improved clinical outcomes and subsequent cure of the disease (Bizollon, Ahmed et al. 
2003, Veldt, Heathcote et al. 2007, Pearlman and Traub 2011). Furthermore, the starting 
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of IFN monotherapy combined with recommendations of prg-IFN and ribavirin, there has 
been a noticeable increase in the number of patients achieving SVR (Jacobson, Gonzalez 
et al. 2005). IFN, although incompletely understood, acts as a direct anti-viral along with 
acting on the host’s immune system, ribavirin on its own is unable to fully constrain the 
replication of HCV much expressively but enhances the anti-viral action of IFN (Chung, 
Gale et al. 2008).  
However, the general response to therapy largely depends on the viral genotype 
and characteristics of the patient. Patients having different hepatitis C genotypes tend to 
react differently to IFN-alpha (Manns, McHutchison et al. 2001, Fried, Shiffman et al. 
2002). This is largely due to the fact that the genotype is one of the strongest prognostic 
aspects of SVR (Zein, Rakela et al. 1996, Idrees and Riazuddin 2009). Genotype 1 is the 
viral strain that is most prevalent and most difficult to treat. More SVR was observed in 
patients suffering from hepatitis C genotype 2 or genotype 3 – more so when compared to 
HCV-infected hosts having genotype 1. Patients that suffer from HCV genotype 2 or 3 
tend to show 75% SVR while people with the HCV genotype 1 have been reported to 
show 40% SVR (Veldt, Brouwer et al. 2003, Jeffers, Cassidy et al. 2004). 
However, there are certain percentages that are not easy to treat. These may 
include people who do not respond to treatment when exposed to IFN-based therapies in 
the past, hosts that are suffering from severe liver fibrosis or cirrhosis, and individuals co-
infected with HIV (Bourliere, Ouzan et al. , Poynard, Moussali et al. 1999, Jackson 2009, 
Lerias de Almeida, Alves de Mattos et al. 2010). There are however, no approved options 
for treatment in the case of people failing to respond to prior treatments. Conducted 
studies so far indicate that retreatment with extending the treatment duration can improve 
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SVR rates to 20% in non-responders (Goncales, Moma et al. 2010). Patients with HIV 
co-infection usually exhibit a delayed response, studies conducted on patients that are 
also infected with the HIV virus have exhibited SVR rates ranging from 17% to 62% 
(Carrat, Bani-Sadr et al. 2004, Torriani, Rodriguez-Torres et al. 2004). This could be 
down to a combination of two primary reasons – because of an increased viral load in the 
co-infected cases and the deficiency in the host’s immune system.  
 
Figure 4 Hepatitis C virus (HCV) viral cycle and targets for drug development 
The HCV lifecycle starts with virion attachment to its specific receptor. The HCV RNA genome 
serves as a template for viral replication and as a viral messenger RNA for viral production. It is 
translated into a polyprotein that is cleaved by proteases. Then, viral assembly occurs. Potentially, 
each step of the viral cycle is a target for drug development. 
This image is originally from Asselah T, Marcellin P. Liver Int. 2013 Feb,33 
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Current interferon based therapies, while already marred with inadequate response 
rates, also have numerous side effects associated with them (McHutchison, Gordon et al. 
1998, Manns, McHutchison et al. 2001). As a result, there has been growing focus on 
coming up with new interferon-free approaches that target various steps of the viral 
lifecycle as either replacements or further improvements for current strategies. This has 
resulted in developing several agents associated with targeting specific viral components 
(Stedman 2012). There have been major advancements during last several years with 
large numbers of ongoing trials with various direct-acting antivirals showing high 
potency, favorable tolerability profile, higher barrier to resistance, shortened treatment 
duration, all oral regimen, pan-genotypic (Asselah and Marcellin 2013). Presently there is 
increased emphasis in the development of more encouraging new agents such as 
polymerase inhibitors and protease. Moreover, there have been numerous compound 
inhibitors that have been designed successfully of the NS3 protease. They are 
subsequently an integral course of action spearheading pre-clinical and clinical 
development. BILN 2061 played a vital part in understanding the importance of these 
particular class of compounds, providing at least a decrease of 2 or 3 log10 in hepatitis C 
load within a timeframe of 48 hours (Lamarre, Anderson et al. 2003). Additionally, 
several NS5B polymerase compound inhibitors are also undergoing clinical development 
based on their encouraging results (Gane, Roberts et al. 2010, Le Pogam, Yan et al. 
2012). In 2011, The U.S. Food and Drug Administration (FDA) approved Victrelis 
(boceprevir) and Incivek (telaprevir), known as inhibitor of HCV protease, for the 
treatment of hepatitis C. In late of 2013, FDA approved Olysio (simeprevir), a new 
therapy to treat chronic HCV infection. Most recently, a phase 2 clinical trial gave 
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encouraging result, treatment with Sofosbuvir and ledipasvir fixed-dose combination 
achieved over 95% SVR12 (sustained virological response 12 weeks after treatment) in 
patients with genotype 1 HCV infection, similar SVR12 was achieved even in those who 
previously had virological failure after receiving a protease inhibitor treatment (Lawitz, 
Poordad et al. 2013). The observation that hepatitis C virus (HCV) could only replicate in 
miR-122-positive hepatocytes led to the discovery that miR-122 is essential for HCV 
replication, and miR-122 is now one of the crucial host factors for anti-HCV therapy 
(Henke, Goergen et al. 2008, Lanford, Hildebrandt-Eriksen et al. 2013). Currently, the 
most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic 
acid-modified oligonucleotide antagonizing miR-122, which is currently in phase 2 
clinical trials for treatment of HCV infection (Janssen, Reesink et al. 2013). 
Various factors ranging from treatment related, host characteristics, viral related 
and disease related, may cause resistance to IFN therapy (Pawlotsky 2003, Chen, 
Borozan et al. 2005, Puig-Basagoiti, Forns et al. 2005). In addition to that, the apparent 
generation subsequent selection of resistant variants may lead to the virus escaping the 
anti-viral pressure that is exerted by HCV-targeting drugs. Verily, mutations pertaining to 
the polymerase and protease enzymes have been identified already (Tomei, Altamura et 
al. 2003, Lin, Lin et al. 2004, Lu, Pilot-Matias et al. 2004, De Francesco and Migliaccio 
2005, Lin, Gates et al. 2005, Le Pogam, Jiang et al. 2006, Le Pogam, Kang et al. 2006, 
Tong, Chase et al. 2006, Koev, Dekhtyar et al. 2007). Mutations of drug-targeted viral 
protein occur rapidly, causing resistance to treatment and leading to treatment failure 
(Rong, Dahari et al. 2010, Pawlotsky 2011). Various mutations are known to exhibit 
either an increased or decreased level of resistance along with the changing of the overall 
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prevalence of individual mutations through the passage of time during the treatment 
stage. In vitro data further suggests a seemingly lowered probability entailing the cross 
resistance between a certain number of the diverse anti-HCV drugs (Tomei, Altamura et 
al. 2003, Lin, Lin et al. 2004, Lu, Pilot-Matias et al. 2004, De Francesco and Migliaccio 
2005, Lin, Gates et al. 2005, Le Pogam, Jiang et al. 2006, Le Pogam, Kang et al. 2006, 
Tong, Chase et al. 2006, Koev, Dekhtyar et al. 2007). Adding to that, molecular biology 
seems to suggest no cross-resistance between protease and polymerase inhibitors (De 
Francesco and Migliaccio 2005). Based on those studies, it is advisable to use agents that 
show a low probability of cross-resistance to supplement the therapy, such as different 
inhibitors or an inhibitor plus pegIFN-alpha. Indeed, administrating telaprevir together 
with pegIFN-α2a or further combined with ribavirin seemed to prevent viral rebound 
(Sarrazin, Rouzier et al. 2007). Simeprevir has also shown to increase the rate of 
sustained virologic response among treatment-experienced patients with HCV genotype-1 
infection (Zeuzem, Berg et al. 2013) 
 
6. Acute, chronic infection and viral clearance 
Acute hepatitis C infection usually occurs during the first six-month time-bracket 
following the onset of viremia. It is usually asymptomatic since merely a minority of 
patients (10%–15%) is known to report symptoms (Ozaras and Tahan 2009). The 
symptoms of acute hepatitis C infection include a noticeable decrease in appetite, 
increased fatigue, consistent abdominal pain, jaundice, repetitive itching, and symptoms 
similar to a case of flu. When the time these symptoms come forth, usually they are 
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related to a comparatively high rate of spontaneous clearance (Gerlach, Diepolder et al. 
2003). Spontaneous viral clearance rates can be considerably varied —between 10% - 
60% of HCV infected individuals (Lehmann, Meyer et al. 2004, Micallef, Kaldor et al. 
2006, Santantonio, Medda et al. 2006). HCV is usually detectable in the blood by PCR 
within a timeframe ranging from one - three weeks after contracting the infection. Serum 
viral load tends to increase considerably during the early stages of infection without any 
clear-cut evidence of liver damage. The responses with respect to the cellular immune are 
usually evident first among circulating T cells 4 to 8 weeks after the beginning of 
infection (Thimme, Oldach et al. 2001, Woollard, Grakoui et al. 2003, Cox, Mosbruger et 
al. 2005). The start of cellular immunity is consistent with a spike in serum transaminases 
which may subsequently suggest a transient immune-associated liver injury (Thimme, 
Oldach et al. 2001). 
Although spontaneous viral clearance occurs in a minority of patients during acute 
infection stage, recurring infections are quite common, and most patients along the way 
are seen to develop chronic hepatitis C (Micallef, Kaldor et al. 2006). Chronic HCV 
occurs when the infection bearing the hepatitis C virus persists for more than a period of 
six months. Clinically though, it is often asymptomatic in nature and is mostly discovered 
by accident due to elevated liver enzymes (Hoofnagle 2002). The natural course of 
chronic hepatitis C could be varied from person to person. While documented cases of 
hepatitis C usually suggest almost most people suffering from an inflammation on liver 
biopsy, the progression rate entailing liver fibrosis is considerably variable among 
patients. Within the untreated population, roughly 33.3% progress to liver cirrhosis 
within a period of 20 years while an additional one-third of the remaining portion have 
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been known to progress to cirrhosis within a period of 30 years (Poynard, Ratziu et al. 
2000, Poynard, Ratziu et al. 2001, Ghany, Kleiner et al. 2003). Usually, factors adjudged 
to have a bearing on the rate of the hepatitis C disease’s progress include classifications 
like age (the higher the age, the increased chances of rapid progression) (Poynard, 
Bedossa et al. 1997, Poynard, Ratziu et al. 2001), gender (men have been known to 
experience more rapid progression of the disease than women) (Wiese, Berr et al. 2000, 
Rodriguez-Torres, Rios-Bedoya et al. 2006), alcohol consumption (directly proportional) 
(Wiley, McCarthy et al. 1998), HIV co-infection (direct relation) (Rotman and Liang 
2009, Konerman, Mehta et al. 2014), and fatty liver (positive correlation) (Younossi, 
McCullough et al. 2004, Younossi, Afendy et al. 2009, Younossi and McCullough 2009, 
Bhala, Angulo et al. 2011). 
 
7. Immune response and HCV infection 
Immune activation is associated with HCV infection. An immune response 
induced by HCV infection is characterized as rapid innate immune response and delayed 
adaptive immune response, regardless of the outcome of the disease progression 
(Shoukry, Grakoui et al. 2003, Dustin and Rice 2007). Innate immune activation was 
observed at the early stage after HCV infection in chimpanzees (Bigger, Guerra et al. 
2004). Inflammatory cytokines also have been shown to be up-regulated in chronically 
HCV-infected individuals (Polyak, Khabar et al. 2001). Studies estimate that in the case 
of an infected chimpanzee at the peak of viremia, ten percent of the hepatocytes support 
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HCV replication at max (Bigger, Brasky et al. 2001). This goes on to suggest that an anti-
viral state is induced quite early in the liver during HCV infection. 
7.1 Innate immunity 
HCV is usually recognized by pathogen recognition receptors (PRRs) which 
further goes on to initiate an innate immune response against HCV infection. Engagement 
of those receptors may activate and subsequently translocate latent IRF-3, further going 
on to activate the IFN-β promoter (Saito, Owen et al. 2008). Intrahepatic interferon 
signaling was observed and associated with HCV viremia, regardless of the outcome of 
the disease progression (Su, Pezacki et al. 2002, Thimme, Bukh et al. 2002). The cellular 
source of interferon is not certain however. 
Several different cell types within the liver may take part in innate immune 
surveillance on HCV infection, including hepatocytes, Kupffer cells (KCs) that serve as 
resident liver macrophages, DCs and natural killer cells (NKs) (Crispe 2009). The first 
immune response to HCV infection was thought to be interferon induction in infected 
hepatocytes (Bigger, Guerra et al. 2004). Hypothetically, infected hepatocytes produce 
the first interferon, which acts on surrounding cells and amplifies interferon signals. 
Several studies showed that HCV infection induced IFN signaling in immortalized human 
hepatocytes (Kanda, Steele et al. 2007) or hepatoma cell lines (Lau, Fish et al. 2008). 
There is no direct evidence of interferon induction in hepatocytes of HCV patients in 
vivo, but intrahepatic interferon-induced genes were detected in infected chimpanzees 
(Lau, Fish et al. 2008). Type I IFNs production - as a reaction to hepatitis C infection - 
may lead to an antiviral state with respect to the surrounding cells. Plasmacytoid DCs 
21 
 
(pDCs) were reported to be activated by HCV-infected hepatocytes through cell-cell 
contact, resulting in producing type I IFN in vitro (Takahashi, Asabe et al. 2010). 
However, in vivo study has not supported pDCs as the source of intrahepatic interferon 
during HCV infection (Lau, Fish et al. 2008). 
Kupffer cells form the highest percentage of tissue-resident macrophages in the 
liver (Laskin, Weinberger et al. 2001). Kupffer cells are responsible for the recruitment of 
CTLs and APCs to eliminate infected cells in the liver (Uwatoku, Suematsu et al. 2001), 
and they also carry out an important function in modulating inflammation in liver fibrosis 
development (Liu, Tao et al. 2010). NK cells are found to be in high quantity in the liver 
and are also essential early responders during HCV infection. NK cells facilitate lysis of 
infected cells and produce IFN-γ that control viral infection (Kokordelis, Kramer et al. 
2013). NK cells may also contribute to maturation of DCs and bridge the gap between 
innate and adaptive immunity. The importance of NK cells in the resolution of HCV 
infection is revealed by the observation of genetic polymorphisms that affect the 
threshold of NK cell activation and influence the outcome of HCV infection (Khakoo, 
Thio et al. 2004).  
7.2 Adaptive immunity 
Controlling acute HCV infection is related to strong, broad directed, and most 
importantly a sustainable activation of hepatitis C-specific T cells (Thimme, Oldach et al. 
2001, Thimme, Bukh et al. 2002, Flynn, Dore et al. 2013). The activation of T cell can be 
transiently observed at least, as hepatitis C is able to establish infection persistently 
(Ulsenheimer, Lucas et al. 2006). However, in the case of majority of the patients, cell-
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mediated immunity is unable to eliminate hepatitis C infection completely (Guobuzaite, 
Chokshi et al. 2008). Even in the case of humans and chimpanzees, the chances of 
contracting reinfections through homologous and heterologous hepatitis C strains remain 
a plausible outcome. Protective immunity on the other hand can reduce the overall 
duration and extent of viremia in the case of repeated infection (Major, Mihalik et al. 
2002, Mehta, Cox et al. 2002, Lanford, Guerra et al. 2004), but completely sterilizing 
immunity has still evaded proof.  
Spontaneous resolution of hepatitis C is commonly linked with a strong and 
sustained T cell response that targets multiple hepatitis C epitopes at once and with 
intrahepatic production of IFN-γ (Cooper, Erickson et al. 1999, Lechner, Wong et al. 
2000, Thimme, Oldach et al. 2001). HCV-specific CD4+ T cell activation is relatively 
easy to detect during the early stage of acute infection than in chronic infection (Lechner, 
Wong et al. 2000). Epitope-specific T cells can be identified when stained with MHC 
class I or class II tetramer peptide complexes. Tetramer-staining T cells may not be active 
in a functional capacity during acute or chronic infection. Indeed, studies conducted have 
shown that a significant percentage of hepatitis C-specific T cells have a “stunned” 
phenotype, even in the case of those hosts that go on to resolve infection (Lechner, Wong 
et al. 2000, Thimme, Oldach et al. 2001). Resolution of acute infection is associated with 
T cell recovery of an activated phenotype and the ability to produce IFN-γ. The broad 
patterns of CD4+ and CD8+ T cell specificities in individuals with resolved hepatitis C 
infection varies substantially with the rather limited amount of hepatitis C epitopes that 
are targeted by T cells with respect to people having chronic infection (Day, Lauer et al. 
2002) (Lauer, Ouchi et al. 2002).  
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The role of humoral immunity to HCV is yet to be comprehended accurately. 
Seroconversion is seen to be a comparatively delayed phenomenon in the case primary 
hepatitis C infection (Netski, Mosbruger et al. 2005). The response of antibodies are not 
required for clearance of acute infection (Cooper, Erickson et al. 1999, Thimme, Bukh et 
al. 2002, Logvinoff, Major et al. 2004) and likely to diminish after spontaneous recovery 
(Takaki, Wiese et al. 2000). Studies suggest that broadly reactive neutralizing antibodies 
(nAbs) that target the viral envelope can be found in the serum of persistently infected 
hosts (Bartosch, Bukh et al. 2003, Logvinoff, Major et al. 2004, Meunier, Engle et al. 
2005). However, the overall development of nAbs is substantially delayed in the case of 
acute infection (Logvinoff, Major et al. 2004, Netski, Mosbruger et al. 2005). In the event 
that patients remain persistently infected in spite of the presence of high titers of nAbs 
may subsequently indicates that nAbs do not facilitate sterilizing immunity, possibly 
because of continued viral mutation and antibody-dependent selection. 
 
8. TLR7 and TLR8 
Receptor-mediated detection of pathogen-derived nucleic acids helps to protect 
genomic nucleic acid in the event of foreign genetic material invasion. A number of 
pattern recognition receptors (PRRs) have been known to participate in the recognition of 
nucleic acid (Barbalat, Ewald et al. 2011). Generally speaking, PRRs can be classified 
into numerous families. The Toll-like receptor (TLR) family is known to consist of ten 
members. Moreover, viral RNA bearing certain traits can also be detected by members of 
the RIG-I-like RNA helicase (RLH) family, such as RIG-I and MDA-5. TLRs along with 
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the two RLH members namely RIG-I and MDA-5 can be differentiated with respect to 
their cellular localization, ligand specificity along with downstream signaling pathways 
(Thompson and Locarnini 2007, Thompson, Kaminski et al. 2011, O'Neill, Golenbock et 
al. 2013). Thus it suggests that host cells can employ several, non-redundant defense 
mechanisms in the detection of invading pathogens. While RIG-I and MDA-5 can be 
classified as cytosolic receptors (Barral, Sarkar et al. 2009), the four members of the TLR 
family (TLR3, TLR7, TLR8, and TLR9) involved in viral nucleic acid recognition are all 
present in the endosomal membrane (Lee and Barton 2014). TLR3 and MDA-5 recognize 
long double-stranded RNA (Liu, Botos et al. 2008, Wu, Peisley et al. 2013). Either 
single- or double-stranded RNA belonging to the triphosphate group at the 5’ end was 
observed to be the ligand for RIG-I (Hornung, Ellegast et al. 2006), and also the ligand 
for TLR9 is DNA-containing CpG motifs (Rutz, Metzger et al. 2004). TLR7 and TLR8 
detect single-strand RNA with certain motifs (Heil, Hemmi et al. 2004).  
Sequence comparisons across vertebrate TLRs go on to reflect that TLR7 and 
TLR8 are the most closely related of the nucleic acid–sensing TLRs (Roach, Glusman et 
al. 2005, Mikami, Miyashita et al. 2012). In humans, remiquimod in known to stimulate 
TLR7 and TLR8, yet the related imidazoquinoline, imiquimod, predominantly activates 
TLR7, indicating considerable differences in ligand specificity and functions between the 
respective receptors (Gorden, Gorski et al. 2005, Larange, Antonios et al. 2009). As far as 
humans are concerned, TLR7 and TLR8 are able to aptly recognize distinct sequence 
motifs in ssRNA (Heil, Hemmi et al. 2004, Hornung, Guenthner-Biller et al. 2005, 
Forsbach, Nemorin et al. 2008). Expression of TLR7 and TLR8 is mainly limited to 
immune cell subsets. Moreover, in the human system, the expression of TLR7 is 
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restricted to PDCs and B cells. TLR8 is predominantly expressed in cells belonging to the 
myeloid lineage, such as monocytes, myeloid dendritic cells, and macrophages (Krug, 
Towarowski et al. 2001, Hornung, Rothenfusser et al. 2002). This differential expression 
is most likely to explain the distinct cytokine profiles influenced by TLR7 and TLR8 
ligands in human cells (Gorden, Gorski et al. 2005). Whereas TLR7 and TLR8 are 
regulated by cytokines and can be induced upon cell activation, recent reports have 
indicated that NK cells and T cells also express these TLRs in some instances (Hart, 
Athie-Morales et al. 2005, Song, Zhuang et al. 2009). 
When receptor/ligand interacts, TLR7 and TLR8 recruit the universal TLR 
adaptor protein MyD88 through its TIR domain (Hemmi, Kaisho et al. 2002, O'Neill and 
Bowie 2007). Instead, MyD88 recruits IRAK1 and IRAK4. IRAK4 then goes on to 
activate IRAK-1 by phosphorylation (Uematsu, Sato et al. 2005, Kim, Staschke et al. 
2007). Both IRAK-1 and IRAK4 leave the MyD88-TLR complex and link up temporarily 
with TRAF6, which leads to its ubiquitination (Kawai, Sato et al. 2004). After 
ubiquitination, TRAF6 is able to form a complex with TAB2/TAB3/TAK1, inducing 
TAK1 activation (Besse, Lamothe et al. 2007). TAK1 then links up to the IKK complex 
which leads to the phosphorylation of IκB and the consequent nuclear localization of NF-
κB (Adhikari, Xu et al. 2007). Activation of NF-κB induces the production of pro-
inflammatory cytokines. Moreover, TLR7/8 can bind with MyD88 and activate IRAK1 
and TRAF6. TRAF6mediates IRF-5 ubiquitination, which is important for IRF-5 nuclear 
translocation and interferon induction (Schoenemeyer, Barnes et al. 2005, Balkhi, 
Fitzgerald et al. 2008). Engagement of TLR7 or TLR8 may also activate IRF7 through 
activation of MyD88, BTK, and TRAF6 (Konno, Yamamoto et al. 2009). Formation of 
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the MyD88-TRAF6-IRF7 complex induces phosphorylation and IRF7 activation. 
Activation of IRF5 and IRF7 results in induction of type I interferon (Lazear, Lancaster et 
al. 2013). 
 
9. Role of TLR7 in immune response against HCV infection 
TLR7, which induces a strong type I interferon in pDCs and hepatocytes when it 
is engaged, has been expected to play an instrumental immunological role in HCV 
infection (Gibson, Lindh et al. 2002, Sagan and Sarnow 2010, Takahashi, Asabe et al. 
2010). Indeed, TLR7 agonists have been shown remarkable antiviral activities by in vitro 
and in vivo studies. It was reported by several groups that TLR7 engagement initiated a 
strong innate immune response against HCV infection. TLR7 agonists have induced an 
antiviral response in hepatoma cell lines through both interferon-dependent and 
interferon-independent mechanisms (Lee, Wu et al. 2006). The potential of TLR7 agonist 
for hepatitis C therapy has been estimated (Lee, Wu et al. 2006, Thomas, Laxton et al. 
2007), and the efficiency and safety of those compounds are under evaluation in clinical 
trials. The administration of TLR7 agonist results in significant interferon induction and 
suppression of viremia (up to 3 log10) (Horsmans, Berg et al. 2005, Bergmann, de Bruijne 
et al. 2011, Fidock, Souberbielle et al. 2011). Recently, Erilka et al. have proved the 
involvement of TLR7 in induction of interferon by HCV and in antiviral response against 
HCV infection. Knockdown of TLR7 in hepatoma cell lines abolished the induction of 
interferon-β. Recently Erilka et al. have proved the involvement of TLR7 in induction of 
interferon by HCV in cell lines that was highly permissive to HCV (Eksioglu, Zhu et al. 
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2011). However, the role of TLR7/8 in detection of HCV RNA by APCs remains 
unknown.  
          The potential implication of TLR7 in the innate immune response against HCV 
was postulated, nevertheless little is known about it and it is not fully demonstrated. In 
fact, pDCs have been shown to be able to be stimulated by infected Huh-7 cells in cell-
culture by recognizing the viral RNA likely via a TLR7-dependent pathway (Python, 
Gerber et al. , Takahashi, Asabe et al. 2010). Moreover, the presence of a GU-rich 
fragment in HCV genome was shown to be detected by TLR7 (Zhang, Guo et al. 2009). 
Furthermore, the single nucleotide polymorphisms (SNPs) in TLR7 and TLR8 were 
associated with the magnitude of inflammation and fibrosis during HCV infection, with 
the response to IFN-α-based therapy and with the susceptibility to the infection with 
HCV (Schott, Witt et al. 2008, Wang, Eng et al. 2011). However, the role of TLR7 in 
HCV detection in APCs and the mechanisms leading to this detection are not known. 
Additionally, the role of TLR8 in the innate immune response against HCV is not known. 
10. HCV detection by antigen-presenting cells 
Antigen-presenting cells (APCs) are crucial for initiation of antiviral immunity. 
APCs sense viral components via PRRs to induce an innate immune response, they also 
capture viral antigens and present to naïve T cells to elicit an adaptive immune response. 
HCV-specific T cells were detected in HCV-infected chimpanzees and humans, 
regardless of the outcome of the disease progression, suggesting the capability of APCs 
for HCV uptake. However, although the immunogenicity of HCV components (RNA or 
proteins) have been shown, DCs appear “silent” when they encounter HCV. Many efforts 
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have been made to prove the immunogenicity of HCV particles, but the only common 
element in these studies is the unresponsiveness of DCs to HCV stimulation. Neither DC 
maturation nor induction of cytokines was observed (Shiina and Rehermann 2008, Liang, 
Russell et al. 2009, Zhang, Guo et al. 2009, Takahashi, Asabe et al. 2010). The 
mechanisms of DC tolerance to HCV are mysterious, and the causes that endow HCV 
with an “undetectable” character remain unknown. The HCV uptake capability of DCs 
still remains controversial. The internalization of HCV-like particles by DCs (Ludwig, 
Lekkerkerker et al. 2004, Barth, Ulsenheimer et al. 2005) and the absence of HCV in DCs 
from HCV infected-patients (Rollier, Drexhage et al. 2003, Longman, Talal et al. 2004) 
have both been reported. The presence of the HCV genome in blood cells, which includes 
DC, has been depicted in numerous studies through reverse transcription (RT)-PCR. 
However, the presence of viral RNA does not explain whether HCV enters cells or 
merely sticks to their surface. Recently, it has been shown that PBMCs are certainly not 
susceptible to HCV (Cormier, Tsamis et al. 2004), HCV in PBMCs from patients are 
mainly carried on the surface of cells (Natarajan, Kottilil et al. 2010). Freshly isolated 
plasmacytoisd DCs (pDCs) and myeloid DCs (mDCs) are not susceptible to pseudotype 
HCV, however, incubation with GM-CSF makes mDCs highly susceptible to pseudotype 
HCV (Kaimori, Kanto et al. 2004). In contrast, Monocyte-derived DCs (mDDCs) appear 
to have great capability for HCV uptake, which depends on DC-SIGN that is induced by 
GM-CSF/IL-4 (Ludwig, Lekkerkerker et al. 2004, Barth, Ulsenheimer et al. 2005). 
The trail by which DCs are able to internalize antigens for presentation of T cells is 
receptor-mediated endocytosis, in which C-type lectins act in an important capacity. An 
increasing number of C-type lectins with specificity for mannosylated antigens have been 
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discovered to be expressed by DCs such as Langerin (Valladeau, Ravel et al. 2000), 
mannose receptor (Sallusto, Cella et al. 1995), DEC-205 (Kato, Neil et al. 1998), and 
DC-SIGN (Engering, Geijtenbeek et al. 2002). Studies suggest that DC-SIGN is 
understood to play an active in infection of DCs by the dengue virus (Navarro-Sanchez, 
Altmeyer et al. 2003, Tassaneetrithep, Burgess et al. 2003), another member of the 
Flaviviridae family. Recently, studies depicting recombinant HCV envelope glycoprotein 
2 (E2) and HCV pseudotype particles (HCVpp’s) have indicated that DC-SIGN and its 
liver-expressed homologue L-SIGN are vital receptors for HCV envelope glycoproteins 
E1 and E2 (Pohlmann, Zhang et al. 2003, Lozach, Amara et al. 2004, Ludwig, 
Lekkerkerker et al. 2004). Both HCV E1 and E2 are able to bind the same binding site on 
DC-SIGN as HIV and mycobacteria. Remarkably, internalized HCV virus-like particles 
were targeted towards non-lysosomal compartments within immature DCs in a not so 
dissimilar manner to that established for HIV-1 (Ludwig, Lekkerkerker et al. 2004), 
suggesting that HCV may target DC-SIGN to escape detection and facilitate viral 
dissemination. 
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HYPOTHESIS AND OBJECTIVES 
 
 
Hypothesis:  
Immune response induced by HCV infection is characterized as rapid innate immune 
response and delayed adaptive immune response (Dustin and Rice 2007), regardless of 
the outcome of the disease progression. Innate immune activation was observed at an 
early stage after HCV infection in chimpanzees (Bigger, Brasky et al. 2001). Antigen 
presenting cells (APCs) are deemed to be responsible for HCV detection, however, the 
mechanisms of immune activation induced by HCV infection has been difficult to clarify. 
It has been shown that HCV RNA is capable to induce anti-viral response (Saito, Owen et 
al. 2008, Zhang, Guo et al. 2009), nevertheless, the detection of HCV by APCs still 
remains elusive. Furthermore, the single nucleotide polymorphisms (SNPs) in TLR7 and 
TLR8 were associated with the magnitude of inflammation and fibrosis during HCV 
infection, with the response to interferon based therapy and with the susceptibility to the 
infection with HCV (Schott, Witt et al. 2008, Wang, Eng et al. 2011). However, the role of 
TLR7 and TLR8 in HCV detection by APCs and the mechanisms leading to this 
detection are still not known. We speculate that APCs has a unique way to detect HCV 
and TLR7/8 is involved in this process. 
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Objectives 
1. Determine the capacity of HCV RNA to induce immune response. Is HCV RNA 
able to induce inflammatory cytokine? Dose HCV RNA contains GU-rich motifs 
which may be recognized by TLR7/8? Are those GU-rich sequences able to 
induce inflammatory cytokine and DC maturation? 
2. Determine the role of TLR7 and TLR8 in HCV RNA detection. Does HCV RNA 
specifically trigger TLR7/8? Are those GU-rich sequence selected from HCV 
genome able to induce cytokines in similar profile as validated TLR7/8 agonist? 
3. Determine the immune response induced by HCV RNA in different antigen 
presenting cells (APCs) and the anti-viral activity of such immune response. Does 
HCV RNA induce type I interferon? Do cytokines produced by APCs upon HCV 
RNA stimulation inhibit HCV replication? 
4. Determine the role of different APCs in HCV detection and anti-HCV immune 
response. Are APCs able to respond to HCV particles? Is there any preference of 
APCs in HCV detection? Does HCV induce type I interferon in APCs? Is there 
any difference between the immune response induced by HCV RNA and particle? 
What are the mechanisms involved in HCV detection by APCs?  
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CHAPTER 2 
HCV derived ssRNA induce innate immune response 
against HCV infection via TLR7 and TLR8 
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Abstract 
 
The hepatitis C virus (HCV) is a positive single-stranded RNA (ssRNA) virus that 
replicates in the liver and has infected 200 million people worldwide. Recognition of 
HCV-associated molecular patterns is crucial for initiation of innate immune response 
against HCV infection (Schoggins and Rice 2013). As a ssRNA virus, HCV RNA might 
be detected by Toll-like receptor 7 or 8, an endosomal/lysosomal RNA sensor, resulting 
in induction of type I interferon that limits infection. Although antiviral activities of the 
TLR7 agonist have been reported (Horsmans, Berg et al. 2005, Bergmann, de Bruijne et 
al. 2011), the role of TLRs in recognizing HCV and the induction of an immune response 
against HCV have not been well defined. In this study, we demonstrate that the HCV 
genome contains GU-rich sequences that can specifically trigger TLR7/8. The 
engagement of TLR7/8 by HCV-derived ssRNA results in the maturation of pDC and the 
production of type I interferon, and also leads to induction of inflammatory cytokines and 
chemokines in different APCs. Cytokines produced by monocytes and pDCs upon 
stimulation of HCV-derived ssRNA inhibit HCV production in an IFN-dependent 
manner, whereas HCV-ssRNA and cytokines produced by activated mDCs do not affect 
viral production due to lack of interferon signaling. HCV ssRNA-mediated cytokines also 
down-regulate CD81 expression on huh7.5 in an IFN-independent manner, which might 
inhibit HCV infection. Our results suggest that HCV RNA has the potential to trigger 
TLR7/8, which subsequently initiates an innate immune response against HCV infection. 
Key words: HCV, single-strand RNA, TLR7, TLR8, dendritic cells, interferon, CD81 
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Introduction 
The hepatitis C virus (HCV) is a worldwide public health problem affecting an 
estimated 200 million individuals (Lauer and Walker 2001). There are approximately 3 to 
4 million new cases of HCV infection each year (WHO 2011). No effective anti-HCV 
vaccine currently exists. Only 20% of HCV-infected individuals can be cured by 
spontaneous viral clearance. Approximately 80% of infected individuals develop chronic 
infection (Manns, Foster et al. 2007). The progression of liver disease usually takes 
decades. Up to 20% of those infected may develop complications including cirrhosis, 
liver failure, or hepatocellular carcinoma (Afdhal 2004). Although antiviral therapies 
have improved considerably in recent years, they are associated with significant toxicity 
and are effective in only about one-half of those treated (Manns, Foster et al. 2007). 
Novel anti-HCV drugs targeting HCV proteins that are essential for HCV replication are 
under development. These drugs have achieved great effectiveness in HCV treatment 
(Asselah and Marcellin 2013). However, mutations of target viral proteins occur rapidly, 
causing resistance and failure of treatment (Rong, Dahari et al. 2010, Pawlotsky 2011). 
Thus, a better understanding of immunity against HCV is required to develop a solution 
for hepatitis C. 
Innate immune defenses are essential to control viral infection through 
recognition of viral macromolecular motifs known as pathogen-associated molecular 
patterns (PAMPs). Pathogen recognition receptors (PRRs) recognize PAMPs and initiate 
innate immune responses (Gordon 2002, Janeway and Medzhitov 2002, Arpaia and 
Barton 2011). RNA viruses have the potential to be recognized by RNA sensors of 
immune cells that initiate immune responses against viral infection, i.e., influenza virus 
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(Diebold, Kaisho et al. 2004) and HIV detected by TLR7/8 (Heil, Hemmi et al. 2004). 
HCV is an enveloped positive single-stranded RNA virus that replicates in the liver. 
Several PRRs are involved in HCV recognition (Horner and Gale 2013). Recently, HCV 
RNA was reported to activate an innate immune response by activating the RIG-I 
pathway in hepatocytes (Saito, Owen et al. 2008). As a bridge from innate immunity to 
adaptive immunity, DCs uptake viral particles, then process and present antigens 
expressed by these particles to T-cells (Villadangos and Schnorrer 2007). DCs sense the 
presence of a virus by TLRs present in the endosomes-lysosome where RIG-I is not 
expressed (Thompson and Locarnini 2007). TLR3 and TLR7/8 are known RNA sensors 
in the endosomes-lysosome (Takeda, Kaisho et al. 2003). TLR3 recognizes double-strand 
RNA (dsRNA) (Alexopoulou, Holt et al. 2001). For HCV, dsRNA form exists only 
during viral replication. In the HCV-infected liver, TLR3 might be engaged by debris 
from nearby dying cells (Schulz, Diebold et al. 2005). TLR7/8 recognizes ssRNA in the 
endosomes-lysosome (Heil, Ahmad-Nejad et al. 2003). It is most likely that TLR7 or 
TLR8 senses HCV RNA in APCs. Hence, it is tempting to speculate that the HCV-
genomic ssRNA could be recognized by TLR7 and/or TLR8 and contribute to immune 
activation during HCV infection. Here we investigate the immune response induced by 
HCV RNA and its effect on HCV infection. 
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Results 
1. Identification of ssRNA sequences in HCV genome that stimulate innate 
immune responses 
 
Like many viruses, HCV could be taken-up by DCs and processed through the 
endosomes-lysosome (Barth, Ulsenheimer et al. 2005). Several TLRs that can sense viral 
RNA are present in DCs endosomes-lysosome, such as TLR3, TLR7, and TLR8 
(Thompson and Locarnini 2007). HCV RNA is potentially able to trigger those RNA 
sensors and initiate innate immunity. HCV is a single positive-strand RNA virus. 
Although several RNA sensors have been identified, TLR7 and TLR8, which are 
responsible for detection of single-strand RNA, are most likely the receptors sensing 
HCV RNA.  
First, we investigated the capacity of HCV RNA sequences to stimulate the innate 
immune response. Extracted HCV RNA was fused to DOTAP and incubated with human 
PBMCs. TNF-α was measured at 24hrs by ELISA. As shown in Figure 1A, HCV RNA 
induces TNF-α production by PBMCs (400 pg/ml, p<0.0001), indicating that HCV RNA 
has the ability to trigger innate immunity. Indeed, based on the previous studies that have 
defined the G/U-rich motif as a primary structural feature recognized by TLR7 and TLR8 
(Heil, Hemmi et al. 2004), we selected nine GU-rich ssRNA sequences (HCVL1 to 
HCVL9) that contain 65% G/U or more in the genomic RNA of HCV (Table 1) as 
potential ligands of TLR7 and 8. The ability of those GU-rich RNA to trigger TLR7/8 
was evaluated. For this purpose, 106/ml PBMCs from healthy donors (N = 3) were 
stimulated with 7.5 μg/ml of each ligand for 24 hours, and TNF-α in the supernatant was 
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then measured by ELISA. Three of those GU-rich RNA sequences (HCVL1, HCVL4, 
and HCVL8) elicited TNF-α production (2300, 1800, 2100 and 3400 pg/ml for HCVL1, 
4, 8 and RNA40 respectively, p<0.0001). However, six of those selected GU-rich RNA 
sequences were unable to induce cytokine production (Figure 1B). Those data suggest 
that certain GU-rich sequences, not all, may endow HCV RNA with stimulatory activity. 
In order to validate that the stimulation was induced by RNA and depended on sequences, 
we introduced RNase treatment and U-to-A replacement of RNA sequences. As we 
expected, the stimulatory activities of HCVL1, HCVL4, and HCVL8 were abolished by 
RNase treatment. RNA sequences with U-to-A replacement did not elicit TNF-α 
production (Figure 1.C), demonstrating that the immunogenicity of HCV-derived ssRNA 
requires the RNA containing the GU motif. In addition, blockage of TNF-α production 
was observed in the presence of IRS661, a specific inhibitor of TLR7/8 (Fig 1D). Our 
data further confirmed the specificity of the immune response induced by HCV ssRNA.  
2. Specific recognition of HCV-derived ssRNA by TLR7 and TLR8 
 
To further investigate the capacity and specificity of HCV-derived ssRNA in 
triggering TLR7 and TLR8, we first transfected HEK cells expressing TLR3, TLR7 or 
TLR8 (InvivoGen) with luciferase expression vectors pNifty2-luc, which allows 
luciferase production upon NF-κB activation. Eight hours later, cells were stimulated 
with HCVL1, HCVL4, or HCVL8 for 24hrs, and luciferase activity was measured. Our 
results showed an increase of the luciferase activity when TLR7- and TLR8-expressing 
cells were treated with these ssRNAs (4-, 2- and 3- fold increase for HCVL-1, 4 and 8 
respectively in TLR7 expressing cells, and 15-, 6- and 3- fold increase respectively in 
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TLR8 expressing cells (Figure 2 B and C)). Luciferase activity did not change by using 
HEK cells expressing TLR3 that sense ssRNA (Figure 2). Our data clearly showed that 
three identified GU-rich sequences from the HCV genome act as specific ligands that 
activate TLR7 and TLR8. 
3. Cytokine production and DC maturation upon ssRNA stimulation 
 
In order to investigate the capacity of three identified RNA sequences on the 
induction of cytokines by APCs (including monocyte, mDCs and pDCs), DCs were 
stimulated with 7.5 μg/ml of each identified ssRNA for 24 hours. Production of 
inflammatory cytokines and chemokines were monitored by Cytometric Bead Array 
(CBA). The results showed that HCV-derived ssRNAs strongly induce inflammatory 
cytokines (IL-1β, IL-6, IL-10, TNF-α, and IL-12p70) and chemokines (CXCL9 and 
CXCL10) (Figure 3). Vast amounts of TNF-α and IL-6 were induced in monocyte, mDC, 
and pDC upon stimulation. CXCL9 and CXCL10 were mainly produced by pDCs. IL-1β, 
IL-12, and IL-10 were produced by monocytes and mDCs but barely detected in the 
supernatant of stimulated pDCs. 
As a major source of type I interferon, pDC is always the hotspot for the study of 
innate immunity against HCV infection. Here we also measured IFN-α and IFN-β 
production by pDCs with HCV RNA stimulation (as described above). Moreover, pDC 
maturation upon stimulation with HCV ssRNA was detected by flow cytometry. As 
expected, HCV ssRNA acted as Cl097, an agonist for TLR7 and TLR8. pDCs produced 
vast amounts of IFN-α (1600, 1500 and 1700 pg/ml respectively, p<0.0001) and IFN-α 
(1300, 1000 and 2250 pg/ml respectively, p<0.0001) upon ssRNA stimulation (Figure 
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4A). Maturation markers CD80 and CD86 were also significantly up-regulated (Figure 
4B). Significantly, the RNase treatment or the introduction of U-to-A mutations led to the 
abrogation of their stimulatory effect on pDCs, also confirming the specificity of the 
responses.  
4. Effect of HCV-derived ssRNA-induced cytokines on HCV infection 
 
It has been reported that TLR7 agonists induce type I interferon to suppress HCV 
replication (Bergmann, de Bruijne et al. 2011). Here we examined the antiviral activity of 
HCV-ssRNA-mediated cytokines. Purified monocytes, mDC, and pDC were stimulated 
with identified HCV ssRNA for 24hrs. Cell-free supernatants were harvested and added 
to HCV infected huh7.5 cells. Viral production was measured by real-time PCR at day 3. 
The results showed that the number of HCV in the supernatant was significantly 
decreased (2 to 3 log10) in the presence of HCV ssRNA-induced cytokines. However, 
surprisingly, only supernatants from ssRNA-stimulated monocytes and pDC had antiviral 
activities that suppressed viral production in HCV-infected huh7.5 cells. A similar effect 
was not observed on supernatants from stimulated mDCs (Figure 5 A).  
Since type I interferon was considered a main factor of TLR7-medicated 
cytokines that inhibit HCV replication, a lack of antiviral activity of mDCs may be 
caused by the absence of type I interferon in the supernatant of stimulated mDCs. Thus, 
we examined the interferon activity of supernatants from HCV ssRNA-stimulated 
monocytes, mDC, and pDC. Interferon activity was determined by induction of pStat1 
Y701 phosphorylation. PBMCs were incubated with supernatants from HCV ssRNA-
stimulated monocytes, mDC, and pDC respectively, after 15min incubation. Stat1 Y701 
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phosphorylation in lymphocytes was measured by flow cytometry. Consistent with the 
antiviral activity assay, only supernatants from ssRNA-stimulated monocytes and pDC 
induced Stat1 Y701 phosphorylation (Figure 6). This indicates TLR7/8 engagement 
induced production of type I interferon in monocytes and pDCs but not in mDCs. To 
confirm that suppression of viral production is mediated by type I interferon, an antibody 
against Interferon-Alpha/Beta R2 (IFNAR2) was used to block interferon signaling 
induced by HCV ssRNA-mediated cytokines. The results showed that IFNAR2-blocking 
antibodies restore HCV production in the presence of supernatants from stimulated 
monocytes or pDC (Figure 5B). They also revealed that HCV ssRNA-activated 
monocytes and pDC inhibit HCV production in an IFN-dependent manner. 
 
5. HCV-derived ssRNA-mediated cytokines down-regulate CD81 expression on 
huh7.5 
 
Several cell surface proteins have been suggested to mediate the binding of HCV 
to hepatocytes and/or to be critical for viral entry. Among the acknowledged receptors or 
co-receptors of HCV are CD81 (Pileri, Uematsu et al. 1998), scavenger receptor class B 
type I (SCARB1) (Scarselli, Ansuini et al. 2002), low-density lipoprotein receptor 
(LDLR) (Agnello, Abel et al. 1999), and the recently identified claudin-1 (CLDN1) 
(Evans, von Hahn et al. 2007). As a major receptor for HCV binding and viral entry, 
CD81 plays a critical role in HCV infection (McKeating, Zhang et al. 2004, Lindenbach, 
Evans et al. 2005). CD81-neutralizing antibodies can block HCV infection. It was 
reported that huh7.5 cells with a low level of CD81 expression are less permissive to 
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HCV (Zhang, Zhang et al. 2010). It has been shown that IFN-alpha down-regulates CD81 
on PBMCs in patients with chronic hepatitis C (Kronenberger, Ruster et al. 2001). Thus, 
we examined whether TLR7/8 mediated cytokines modulate CD81 expression on huh7.5 
cells. Huh7.5 cells were incubated with supernatant from TLR7/8-agonist-stimulated 
PBMCs. IFN-α was set as control. After 24hrs, CD81 expression on huh7.5 was 
measured by flow cytometry. Results showed that TLR7/8-mediated cytokines induced a 
significant down-regulation of CD81 expression (Figure7). Compared to CD81 
expression levels on huh7.5 cells (MFI 5118±147) with supernatant from non-stimulated 
PBMCs, CD81 expression on huh7.5 with supernatant from ssRNA-stimulated PBMCs 
was remarkably decreased (MFI, HCVL1 3473±189, HCVL4 3354±192, HCVL8 
3166±301, Cl097 3233±375, P<0.0001). Surprisingly, IFN-alpha treatment barely 
affected CD81 expression (MFI 4682±34), indicating that down-regulation of CD81 is 
mainly elicited by TLR7/8-mediated cytokines other than IFN-α. 
6. HCV-derived ssRNA pretreatment impairs pDCs capacity to produce IFNα 
 
IFN-α produced by pDC is thought to be an important immune response to control 
HCV infection. However, the ability of pDC to produce IFN-α upon in vitro stimulation 
is significantly reduced in HCV-infected individuals (Uno, Suginoshita et al. 2005, 
Dustin and Rice 2007). Recent studies have found that TLR activation in DC causes 
tolerance in response to further stimulation (Assier, Marin-Esteban et al. 2007). 
Therefore, we investigated the effect of pre-exposure to HCV-encoded ssRNA on IFN-α 
production by pDCs response to further stimulation. PBMCs were stimulated with HCV 
ssRNA HCVL1, HCVL4, and HCVL8 for 24h. Cells were washed and then re stimulated 
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with the same HCV ssRNA or Cl097 (TLR7/8 agonist). Brefeldin A was added 2h after 
stimulation. IFN-α production in pDC was detected at 6h by intracellular staining. Our 
results showed that ssRNA or Cl097 could barely induce IFN-α expression in pretreated 
pDC (Figure 8). Our results also showed that the pre-exposure of pDCs to HCV-derived 
ssRNA significantly impaired IFN-α expression upon re-stimulation with TLR7 and 8 
ligands (i.e., HCV ssRNA or Cl097), suggesting that persistent TLR7/8 activation by 
viral RNA triggering induces pDC tolerance during HCV infection. 
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Discussion 
 
PAMPs expressed by pathogens can be detected by PRRs, leading to the initiation 
of innate immune responses against infections (Mogensen 2009). As the HCV genome is 
a positive single-strand RNA, TLR7 and TLR8 very likely play an important role in the 
immune response against HCV. Here, we evaluated the immunostimulatory effect of 
HCV RNA and demonstrated that HCV RNA has the ability to stimulate immune cells 
and induce inflammatory cytokines. Three RNA sequences were identified as TLR7/8 
agonists that induce TNF-α production by PBMCs and specifically trigger TLR7/8. The 
specificity was validated by TLR7/8 inhibitor, RNA mutants and TLR7 or TLR8 
expressing cell lines. Those results revealed that HCV RNA can be recognized by 
TLR7/8 and has the potential to induce immune activation. 
Most studies have focused on TLR7 signaling in pDC (Zhang, Guo et al. 2009), as 
pDC is considered the main source of IFN-α. Some studies have focused on the antiviral 
activity of the TLR7 agonist in hepatocytes (Lee, Wu et al. 2006), as they are the main 
target of HCV. However, HCV also can be captured by antigen-presenting cells, and viral 
RNA can be detected by TLR7/8 expressed in those cells (Barth, Ulsenheimer et al. 2005, 
Takahashi, Asabe et al. 2010). Here we examined the stimulatory effects of HCV ssRNA 
on monocytes, mDCs, and pDCs. Like the TLR7/8 agonist, HCV-derived ssRNA induced 
inflammatory cytokine production by different APCs subsets. The profile of cytokine 
production is quite different in monocytes, mDCs, and pDCs. The cytokine production 
preference may reveal the different roles of APCs in immune regulation and antiviral 
immunity. Furthermore, most of those cytokines are known to be up-regulated in vivo 
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during HCV infection, and some of them are correlated with disease progression, such as 
TNF-α and IL-8 were known as key factors in liver cirrhosis and resistance to interferon 
treatment (Polyak, Khabar et al. 2001).  
Several agonists of Toll-like receptors have shown great antiviral activities, such 
as agonists of TLR3, TLR4, TLR7/8, and TLR9 (Doyle, Vaidya et al. 2002, Lee, Wu et 
al. 2006, Trapp, Derby et al. 2009, Ong, Wikstrom et al. 2013). Cytokines produced by 
activated PBMCs or hepatic stellate cells strongly inhibit HCV replication (Thomas, 
Laxton et al. 2007, Wang, Trippler et al. 2009). As a strong inducer of type I IFN, the 
TLR7 agonist has been broadly studied for its antiviral activities (Horsmans, Berg et al. 
2005, Lee, Wu et al. 2006, Thomas, Laxton et al. 2007), and the potential of the TLR7 
agonist for clinical therapy of hepatitis C has recently come under evaluation (Bergmann, 
de Bruijne et al. 2011). Here we showed that HCV ssRNA triggers TLR7/8 to initiate 
innate immunity against HCV in an IFN-dependent and independent manner (Figure 5B). 
First, we demonstrated that HCV RNA activated APCs and induced inflammatory 
cytokines. In accordance with previous studies, activated pDC has significant antiviral 
activity. HCV-ssRNA-induced cytokines produced by pDC significantly inhibited HCV 
production. Moreover, supernatants from ssRNA-stimulated monocytes that also 
suppressed viral production in a IFN dependent manner. The inhibitory effect can be 
abolished by neutralizing antibodies against IFN-α/β receptor 2. It indicates that not only 
pDCs but also monocytes contribute to innate immunity against HCV. Conversely, 
supernatants from HCV ssRNA-stimulated mDCs barely affect viral production since 
there is no IFN signaling induced by its supernatant. Those data confirm that interferon is 
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crucial for the control of HCV infection. TLR7/8-mediated cytokines inhibit HCV 
replication in an IFN-dependent manner.  
CD81 is a main receptor for HCV infection. It was reported that IFN-α therapy 
down-regulated CD81 expression on PBMCs in HCV (Kronenberger, Ruster et al. 2001, 
Kronenberger, Herrmann et al. 2006). As we showed above, engagement of TLR7/8 by 
HCV ssRNA resulted in production of type I interferon. Thus, we also examined the 
effect of HCV-ssRNA-mediated cytokines on the expression of CD81 on huh7.5 cells. 
Our results revealed that HCV ssRNA-induced cytokines caused approximately 40% 
down-modulation of CD81 on huh7.5, but a similar phenomenon was not observed on 
huh7.5 with IFN-α treatment, which was expected to be a positive control. It is still 
unclear how IFN-α induced down-regulation of CD81 on PBMCs in HCV infected 
individuals. The differences between our observation and others are probably due to 
different mechanisms. CD81 is a widely expressed surface protein, and it is involved in 
cell activation. CD81 expression on PBMCs was increased in HCV-infected individuals 
(Kronenberger, Ruster et al. 2001, Kronenberger, Herrmann et al. 2006). Up-regulation of 
CD81 might be induced by viral infection or associated immune activation. IFN-α 
therapy suppressed HCV replication, resulting in the decrease of viral replication that 
turned immune activation toward normal levels. Less activation accompanied lower 
CD81 expression on PBMCs. Another possible mechanism is that IFN-α may affect 
CD81 expression by inducing degradation of CD81 directly, but it seems to work 
differently on various cell types (Kronenberger, Herrmann et al. 2006). In our study, 
changes of CD81 expression on huh7.5 are not due to HCV infection. IFN-α may have no 
effect on CD81 expression of huh7.5. Thus, IFN-α may not regulate CD81 expression in 
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the same way as it does on PBMCs in vivo. Cytokines induced by TLR7/8 probably 
decrease CD81 expression by regulation of CD81 transcription or induce CD81 
degradation by proteins, such as PCSK9 (Labonte, Begley et al. 2009).  
Two RNA sensors, TLR7 and RIG-I, have been broadly studied in innate 
immunity against HCV infection. RIG-I was thought to be critical in the detection of 
HCV since the deficient RIG-I was founded in huh7.5, a hepatoma cell line that is highly 
permissive to HCV (Sumpter, Loo et al. 2005, Saito, Owen et al. 2008). However, RIG-I 
is not indispensable for control of HCV replication (Feigelstock, Mihalik et al. 2010), 
both RIG-I and TLR7/8 could be involved in detection of HCV, even in hepatic cells 
(Lee, Wu et al. 2006). In this study, we showed that TLR7/8 also plays an important role 
in induction of innate immunity against HCV. TLR7/8 is expressed in 
endosomes/lysosomes, and RIG-I is expressed in cytoplasm (Thompson and Locarnini 
2007). During the life cycle of HCV infection, viral RNA is released to cytoplasm after 
entry and uncoating, where RNA may be detected by RIG-I, leading to induction of an 
antiviral response (Saito, Owen et al. 2008). APCs capture viruses by different ways 
other than natural infection (Mercer and Greber 2013). HCV can bind to an antigen-
capture receptor like DC-SIGN and be internalized into APCs (Ludwig, Lekkerkerker et 
al. 2004), which are involved in endosomes/lysosomes where viral RNA might be 
exposed to TLR7/8. Both RIG-I and TLR7/8 can sense HCV ssRNA, however, in certain 
cell types such as pDCs, detection of RNA viruses is totally dependent on TLR7 (Lee, 
Lund et al. 2007). Since pDCs is a major source of type I IFN, TLR7 is more important in 
the control of HCV infection. Furthermore, detection of HCV by TLR7/8 occurs before 
synthesis of viral protein starts. Nonstructural proteins of HCV possess the capability to 
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interact with adaptors of TLR or RIG-I pathways that strongly compromise signaling and 
initiation of a consequential response. So it seems TLR7/8 signaling is more efficient as it 
starts without interference of HCV proteins. 
In conclusion, we reveal that HCV RNA contains GU-rich sequences and can 
specifically trigger TLR7/8. Immune activation induced by HCV RNA can suppress 
HCV production in an IFN-dependent manner. It can also down-regulate CD81 
expression in an IFN-independent manner, which might decrease HCV infection. Thus, 
activation of TLR7/8 by HCV RNA may contribute to anti-HCV immune responses, 
however, repetitive stimulation by HCV RNA causes anergy of pDC. 
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Materials and methods 
 
Cell lines and plasmid 
Hepatoma cell huh7.5 (kindly provided by Dr. Charles Rice, Rockefeller University) and 
Hepatoma cell Huh7.5-20 producing JFH1 HCV (Kindly provide by Dr. T. Jake Liang, 
National Institutes of Health) were cultured in DMEM-based complete growth medium. 
293HEK cells expressing TLR3, TLR7 or TLR8, NF-κB inducible plasmid pNiFty2-Luc 
were obtained from invivogen. pNiFty2-Luc contains report gene expression cassette that 
allows firefly luciferase production under control of NF-κB activation. 
Cell isolation 
Human peripheral blood mononuclear cells (PBMCs) were isolated from leukapheresis 
following ficoll procedure. Monocytes were isolated from PBMCs by using human 
monocytes enrichment kit (STEMCELL Technologies Inc, Canada), purity was 
confirmed by staining with CD14-PB. pDCs were isolated from PBMCs by using Human 
Plasmacytoid DC Enrichment kit (STEMCELL Technologies Inc, Canada), and mDCs 
were isolated from PBMCs by using CD1c+ Dendritic Cell Isolation Kit (Miltenyi Biotec 
Inc, USA), purity was confirmed by staining with Linage-Alexa700 (CD3, CD14, CD19, 
CD16), HLA-DR-APC-cy7, CD11c-APC and CD123-PE. Cells were cultured in 
RPMI1640 containing 10% human serum.  
Stimulation of cells and detection of cytokines 
HCV RNA was extracted from supernatant of HCV producing cell line huh7.5-20 by 
using QIAamp Viral RNA Mini Kit (QIAGEN, USA). HCV derived ssRNA containing 
more than 65% GU were selected and synthesized (Integrated DNA Technologies, 
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Canada). HCV RNA or HCV derived ssRNA were incubated with DOTAP for 15min. 
PBMCs, monocytes, mDC and pDC were stimulated with RNA-DOTAP complex for 
24hrs. Supernatants were harvest and TNF alpha production was measured by Human 
TNF alpha ELISA Ready-SET, Type I Interferon was measured by Human Interferon 
alpha ELISA kit and Human Interferon Beta ELISA Kit (PBL Interferon Source, USA), 
inflammatory cytokines and chemokines were measured by Cytometric Bead Array 
(CBA) using Human Inflammatory Cytokine Kit and Human Chemokine Kit (BD 
biosciences, USA). RNA with U to A replacement and RNA with RNase A treatment 
were set as negative control. 
Specificity of TLR7/8 engagement 
5 x104 293HEK cells expressing TLR3, TLR7 or TLR8 were seeded in 96 well plate and 
cultured for overnight. Cells were transfected with pNiFty2-Luc when confluence reaches 
80%. After 8hrs transfection, cells were stimulated with HCV ssRNA that fused to 
lipofectamine 2000 (invitrogen, USA), after 24hrs culture, cells were washed and lysis, 
luciferase activity was measured by Luciferase Assay System (promega, USA). 
Viral production, infection and quantification 
Cell line huh7.5-20 stably producing HCV was cultured in DMEM-based complete 
growth medium for 4 dyas, supernatant was harvested and filtered by 0.45um filter 
(sarstedt, Germany), viral load was quantified by real time PCR and viral stock was 
stored at -80 °C for further use. 2 x104 huh7.5 cells were seeded in 96 wells plate and 
cultured for overnight, then cells were incubated with virus at ratio 10 (RNA/cells), after 
4hrs incubation cells were washed and refilled with fresh medium. For viral RNA 
quantification, viral RNA was extracted from supernatant and real time PCR was 
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performed by using QuantiFast SYBR Green RT-PCR Kit (QIAGEN, USA), forward 
primer 5’-CGGGAGAGCCATAGTGG-3’, reverse primer 5‘-
AGTACCACAAGGCCTTT-3’. RNA standard was prepared by in vitro transcription 
using MEGAscript® T7 Kit (ambion, USA), quantity of RNA was determined by OD260 
and RNA copies were calculated by formula from QIAGEN. 
Suppression of viral production by HCV-ssRNA mediated cytokines 
105 monocytes, mDC, or pDC were stimulated with HCV derived ssRNA for 24hrs, cells 
free supernatants were harvested. 2 x104 huh7.5 cells were seeded in 96 wells plate and 
cultured for overnight, cells were incubated with HCV for 4hrs and then washed, medium 
containing 10% of supernatant from non-stimulated or stimulated monocytes, mDCs or 
pDCs were added. Supernatants for infected huh7.5 were harvested at 72hrs and 
centrifuge at 1500rpm for 5min to remove debris. Viral load was quantified by real time 
PCR as described above. To show interferon dependent suppression, Human IFN-
alpha/beta R2 MAb (Clone MMHAR-2, R&D Systems, USA) were added (10ug/ml) to 
HCV infected huh7.5 and incubated for 1h before adding supernatant from stimulated 
monocytes or pDCs. 
DC maturation marker and CD81 expression by flow Cytometry 
pDCs were stimulated with ssRNA HCVL1, HCVL4, HCVL8 and RNA mutants or 
RNase treated RNA for 24hrs, cells were stained with anti-CD80-FITC and anti-CD86-
PE (bdbiosciences, USA), maturation marker CD80 and CD86 were monitored by flow 
cytometry. Huh7.5 cells were incubated with supernatants from stimulated PBMCs for 
24hrs, cells were stained with anti-CD81-PE (bdbiosciences, USA) and detected by flow 
Cytometry. 
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Statistical analysis 
p-values were determined using two way paired student’s t tests or Newman-Keuls one-
way analysis. p –values less than 0.05 were considered statistically significant. 
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Figure 1: GU-rich sequences in HCV genome induce TNF-α production.  
Identification of ssRNA from HCV genome that stimulates innate immune response  
A. PBMCs were stimulated with DOTAP or extracted HCV RNA that was fused with 
DOTAP for 24hrs. B. Screening of single stranded RNA (ssRNA) sequences of HCV 
genome that are able to stimulate TNF-α production. 106/ml total PBMCs (N=3) were 
stimulated for 24 hours with DOTAP + different ssRNA at 7.5μg/ml. RNA-40 is used as 
a positive control. NS indicates non-stimulated. TNF-α levels were measured in the 
supernatant by ELISA. C. U to A mutant and RNase treatment show specificity of 
stimulation. D. PBMCs (N=3) were stimulated by indicated ssRNA with or without 
TLR7/8 inhibitor IRS661. 
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Figure 2: Specificity of TLR7/8 triggering by HCV derived ssRNA 
293 cells expressing TLR7, TLR8 and TLR3 were transfected with pNfity2-luc which 
allow luciferase expression upon NF-kB activation. Cells were stimulated with HCV 
derived ssRNA for 24h and the luciferase activity was measured. Results are expressed as 
a ratio to luciferase activity observed in stimulated versus non-stimulated cells. 
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Figure 3: Inflammatory cytokines and chemokines production by monocytes, mDCs 
and pDCs.  
105 purified monocytes, mDCs and pDCs were stimulated for 24 hours with different 
ssRNA at 7.5μg/ml. TNF-α, IL6, IL12, IL1b, CXCL9, CXCL10 and IL-10 levels were 
measured in the supernatant by Cytometric Bead Array (CBA). The mutated forms of 
HCVL1, HCVL4 and HCVL8 or treatment with RNAase were used as negative controls. 
NC indicates non-stimulated 
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Figure 4: Maturation and type I IFN production of pDC 
105 purified pDCs were stimulated for 24 hours with different ssRNA at 7.5μg/ml. The 
mutated forms of HCVL1, HCVL4 and HCVL8 or treatment with RNAse are used as 
negative controls. IFN-α (A) and IFN-β (B) production in the supernatant were measured 
by ELISA, DC maturation markers CD80 and CD86 (C) were detected by flow 
cytometry. NS indicates non-stimulated 
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Figure 5: HCV-ssRNA mediated cytokines inhibit HCV production in IFN-
dependent manner.  
A. 105 purified monocytes, mDC, and pDCs from healthy donors (N=3) were stimulated 
for 24 hours with 7.5 µg/ml of identified HCV ssRNA, cell-free supernatants were 
harvested. 2X104 huh7.5 cells were infected by HCV (2X 105 copies). 4 hrs later, Huh 7.5 
cells were washed, medium and supernatants from non-stimulated or stimulated 
monocytes, mDC, and pDCs were added. B. HCV infected huh7.5 cells were incubated 
with or without interferon receptor blocking antibody for 1h, supernatants form 
stimulated monocytes or pDCs were added. 3 days after infection, HCV RNA was 
extracted from the supernatants and quantified by real-time RT-PCR. NS indicates non-
stimulated. N indicates non-treated cells, NS indicates supernatant from non-stimulated 
cells 
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Figure 6: HCV-ssRNA mediated cytokines inhibit HCV production in IFN-
dependent manner. 
106 PBMCs were incubated with supernatants (SN) from HCV ssRNA stimulated 
monocytes, mDC, and pDC respectively, after 15min incubation, cells were fixed and 
stained with antibody against Y701 phosphorylated Stat1. Stat1 phosphorylation in 
lymphocytes was measured by flow Cytometry. Non-stimulated cells (blue), treatment 
with supernatant from non-stimulated PBMCs (red), treatment with supernatant from 
stimulated PBMCs (green). 
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Figure 7: HCV-derived ssRNA down-regulate CD81 expression on huh7.5.  
105 PBMCs were stimulated with cl097 or HCV derived ssRNA for 24hrs, cell-free 
supernatants were added to huh7.5. After 24hrs incubation, CD81expression on huh7.5 
were measured by flow Cytometry. “Naïve”, non-treated cells 
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Figure 8: Impairment of IFN expression in pDC with HCV-derived ssRNA pre-
treatment  
A. PBMCs were stimulated with HCV ssRNA HCVL1, HCVL4 and HCVL8. B. PBMCs 
were stimulated with DOTAP, Cl097, HCVL1, HCVL4 and HCVL8. 24h later, cells 
were washed then re stimulated with indicated ssRNA or Cl097 (TLR7/8 agonist), 
brefeldin A was added 1h after stimulation. IFN expression in pDC was detected by 
intracellular staining (“-“, non-stimulated cells). 
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Abstract 
 
Hepatitis C virus (HCV) is a positive single-stranded RNA (ssRNA) virus that replicates 
in the liver and has infected 200 million people worldwide. Approximately 80% of HCV-
infected individuals become chronically infected. Although immune activation was 
observed after infection in vivo, persistently increased viral load suggests the failure of 
innate immunity to control ongoing infection. Immune activation induced by HCV 
components (proteins or RNA) have been studied, however, the detection of HCV by the 
innate immune system is still poorly understood. In this study, we demonstrate that HCV 
genomic RNA activates antigen-presenting cells (APCs). However, peripheral DCs and 
monocytes do not respond to JFH1-culture-derived HCV (HCVcc). Only macrophages 
sense HCV and produce inflammatory cytokines. HCV stimulation induces inflammatory 
cytokines production (TNF-α, IL-8, IL-6, and IL-1b). Interestingly, macrophages 
stimulated by HCV do not express interferon-beta and interferon-stimulated genes, which 
is very similar to TLR7/8 signaling that is characterized as deficient interferon induction 
in macrophages. TLR7/8 specific inhibitor IRS661 also provides evidence of involvement 
of TLR7/8 in HCV recognition. Furthermore, Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) plays an important role in 
detection of HCV by macrophages. Cytokine production induced by HCV is 
compromised in the presence of a DC-SIGN-blocking antibody. However, monocytes-
derived DC with higher expression of DC-SIGN does not respond to HCV stimulation, 
suggesting detection of HCV is cell-type-dependent, and DC-SIGN is not the only 
determinant in HCV detection. Our results reveal that macrophages have the ability to 
sense HCV and produce inflammatory cytokines but not IFN-α, suggesting that activation 
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of macrophages in HCV-infected individuals may contribute to inflammation but not 
control of viral infection. 
 
Key words: HCV, innate immunity, Dendritic cells, inflammation, DC-SIGN, 
TLR7/8,Macrophages 
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Introduction 
 
The hepatitis C virus, a member of the Flaviviridae family, is an ssRNA virus that 
causes hepatitis C and affects 200 million people worldwide (Lauer and Walker 2001). 
Extrahepatic disease is common and affects an estimated 40% of patients with chronic 
HCV infection (Mayo 2003). HCV infection is now the leading indication for liver 
transplantation (Brown 2005). HCV establishes persistent infection in the majority of 
those who contract it, despite the fact that it is recognized and targeted by innate, cellular, 
and humoral immune mechanisms. The high incidence of chronicity suggests that the 
virus has developed efficient mechanisms to escape host immune responses (Horner 
2013). 
 HCV is recognized by innate virus-sensing mechanisms and induces a rapid 
immune response. Immune activation was observed in HCV-infected individuals (Su, 
Pezacki et al. 2002), but it is still unclear how HCV infection induces immune activation. 
The first defense was thought to be IFN-β produced by HCV-infected hepatocytes 
(Bigger, Guerra et al. 2004, Wieland, Makowska et al. 2013), however, it is still 
controversial whether HCV infection induces interferon production in hepatocytes 
(Cheng, Zhong et al. 2006, Kanda, Steele et al. 2007). Immune response induced by HCV 
infection is characterized as rapid innate immune response and delayed adaptive immune 
response (Dustin and Rice 2007), regardless of the outcome of the disease progression. 
Moreover, cellular immune responses are weak in chronically infected patients (Missale, 
Bertoni et al. 1996). Given the important roles of the innate response in initiation of 
adaptive immunity, impaired cellular response suggests compromised innate immunity 
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and inefficient T cell priming. Persistent increased viral load also implies that innate 
immunity fails to control HCV infection. Activation markers such as CD80, CD40, and 
CD86 on DCs and inflammatory cytokines have been found up-regulated in HCV-
infected patients compared to healthy individuals (Liang, Russell et al. 2009). However, 
the same phenomenon was not observed on DCs that were stimulated with HCV in vitro 
(Shiina and Rehermann 2008). No cytokines were induced in DCs upon direct HCV 
stimulation (Liang, Russell et al. 2009, Zhang, Guo et al. 2009, Takahashi, Asabe et al. 
2010). HCV non-structure proteins have been proposed as the cause of unresponsiveness. 
Indeed, overexpression of NS3, NS4, and NS5A strongly inhibit TLR-mediated cytokine 
production (Abe, Kaname et al. 2007). It was also reported that HCV particles inhibit 
TLR9-induced IFN-α production of pDCs. Interestingly, the inhibitory effect does not 
require DC infection or viral entry (Shiina and Rehermann 2008). However, HCV has no 
effect on cytokine production and DC maturation induced by an influenza virus or LPS 
(Shiina and Rehermann 2008), suggesting that HCV does not alter the capacity of DCs to 
respond to virus or microbe stimulation.  
 It remains unknown whether APCs are able to detect HCV and initiate an innate 
immune response or which type of APCs are responsible for HCV detection. There are 
abundant APCs in the liver where HCV infection mainly takes place. Kupffer cells 
(resident macrophages in the liver), myeloid DCs, and plasmacytoid DCs have been 
described to be involved in the innate immune response against viral infection (Crispe 
2009). Several studies have suggested that HCV can be captured by DCs or DC-SIGN-
expressing cells (Ludwig, Lekkerkerker et al. 2004, Barth, Ulsenheimer et al. 2005, 
Lambotin, Baumert et al. 2010). However, no solid evidence has demonstrated activation 
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of APCs by direct HCV stimulation, although immunostimulatory effects of HCV 
components have been reported (Dolganiuc, Oak et al. 2004, Chang, Dolganiuc et al. 
2007, Zhang, Guo et al. 2009). Thus, in this study, we assessed the capacity of APCs to 
detect HCV and innate immune response induced by virus. 
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Results 
 
1. Macrophages but not monocytes and DCs sense HCVcc 
 
The capabilities of HCV proteins and RNA to activate innate immune cells have 
been reported (Dolganiuc, Oak et al. 2004, Zhang, Guo et al. 2009). Many groups have 
tried to investigate the immune response induced by HCV particles and the mechanism of 
HCV detection by antigen-presenting cells in vitro, but the immunostimulatory effect of 
HCV particles has not been observed (Liang, Russell et al. 2009, Zhang, Guo et al. 2009, 
Takahashi, Asabe et al. 2010). To verify if HCV has the ability to stimulate APCs, 
PBMCs were stimulated with HCVcc at different ratios, extracted viral RNA fused with 
DOTAP was set as positive control, and TNF-α in the supernatants were measured after 
24hrs. Consistent with previous studies, HCV RNA induced TNF-α production (200 
pg/ml, p<0.0001), but PBMCs showed no response to HCVcc stimulation (Figure 1A). 
Considering the low frequency of DCs in PBMCs and in order to identify which subsets 
are involved in HCV detection, we used purified monocytes, pan-DCs, and monocytes-
derived macrophages (MDMs), and examined their responsiveness to HCVcc. Purified 
cells were incubated with HCVcc, and TNF-α in the supernatants were measured after 
24hrs. Results showed that neither monocytes nor pan-DCs responded to HCVcc 
stimulation, and no TNF-α was induced in spite of their all responding to cl097, a 
commercial TLR7/8 agonist (Figures 1B, C). Surprisingly, TNF-α was significantly 
increased in macrophages upon HCVcc stimulation (p=0.01). MDMs generated from 7 
out of 8 donors showed remarkable responsiveness to HCV (Figure1D). Part of the 
donors had higher responses than others. Overall, these data reveal that PBMCs, 
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monocytes, and DCs do not sense HCV. MDMs possess different characters and the 
ability to detect HCV particles leading to immune activation.  
 
2. Induction of inflammatory cytokines by HCVcc stimulation 
 
To show dose-dependent responses to HCVcc stimulation, MDMs from donors 
who had good responsiveness were incubated with HCVcc at different ratios as indicated. 
TNF-α production was monitored for 24hrs by ELISA. Results showed that HCVcc-
induced TNF-α production in a dose-dependent manner (Figure 2A), TNF-α is still 
detectable when virus/cells at 2.5, EC50 of HCV stimulation is at a ratio of 20. MDMs 
and monocytes from 20 donors were stimulated with HCV at a ratio of 20. Results 
showed that MDMs from 19 donors out of 20 responded to HCV stimulation (average of 
1500 pg/ml, p< 0.0001). TNF-α production induced by HCV stimulation varied among 
those 20 donors, indicating that the responsiveness of MDMs to HCV was different from 
one donor to another (Figure 2B). In contrast, no significant TNF-α induction was 
observed in monocytes upon HCV stimulation. Other inflammatory cytokines produced 
IL-6, IL-8, and IL-1 and were also found to be induced in MDMs by HCV (Figure 2C). 
No IL-10 production was detected.  
 
3. HCVcc as well as TLR7/8 agonist do not trigger interferon pathway in 
macrophages 
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Interferon is well known as a key factor in controlling HCV infection. To 
investigate whether macrophages are involved in immunity against HCV infection, we 
monitored IFN-β and IFN-stimulated gene expression in macrophages after 3hrs 
incubation, with HCVcc, LPS, and cl097 set as positive control. Data showed a 
significant increase of TNF-α at 3hrs after HCVcc stimulation, as well as stimulation with 
LPS and cl097. Surprisingly, like TLR7/8 agonist, HCVcc stimulation did not induce 
interferon expression in macrophages. In contrast, up-regulation of IFN-β in 
macrophages with LPS stimulation demonstrated that MDMs were still capable of 
producing IFN-β (Figure 3A). Those results suggest that HCVcc most likely triggers 
TLR7/8 pathway, which is compromised in macrophages and characterized as a lack of 
IFN-β induction (Schroder, Spille et al. 2007). To confirm the deficiency of IFN-β, we 
measured the expression of IFN-stimulated genes at 16hrs after stimulation. Consistent 
with IFN, LPS-induced up-regulation of IFIT1, ISG15, and OAS1in macrophages, HCV 
stimulation led to an increase of TNF-α expression but not those IFN-stimulated genes 
(Fig3 B). It revealed that activation of macrophages by HCVcc stimulation does not 
involve an IFN signaling pathway. 
 
4. Antiviral activity and responsiveness to HCVcc 
 
Although macrophages are differentiated from monocytes, the responsiveness of 
macrophages to HCVcc appears completely different from that of monocytes. Among 
different APCs subsets, macrophages seem the only ones that detect HCV and initiate 
innate immunity, thus, it is alluring to understand the role of activated macrophages in 
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controlling viral infections. As shown above, HCVcc triggers TLR7/8 in macrophages. 
Hence, we investigated the antiviral activity of TLR7/8 agonist-activated macrophages 
and monocytes. Data showed that cl097 up-regulated TNF-α expression in both 
macrophages and monocytes, however, IFN-β expression was increased only in 
monocytes (Figure 4A). Supernatants from Cl097-stimulated macrophages and 
monocytes were added to HCV-infected huh7.5 cells. Consistent with IFN-β induction, 
results showed a significant decrease in viral production by HCVcc infected huh7.5 with 
supernatant from Cl097-stimulated monocytes but not macrophages (Figure 4B). 
Ironically, monocytes have the potential to suppress HCV production, but they are unable 
to detect HCV, macrophages can detect HCV, but they have no antiviral activity when 
TLR7/8 is triggered (Figure 4C). 
 
5. RNA sensors involved in HCV recognition 
 
Several PPRs have been identified as receptors to detect RNA viruses. TLR7/8 
and TLR3 are known RNA sensors in endosomes that recognize ssRNA and dsRNA, 
respectively. Since HCV and TLR7/8 agonists induce similar responses in macrophages, 
and both induce TNF-α but do not activate IFN signaling, it is most likely that HCV 
triggers TLR7/8 in macrophages. Thus, we used TLR7/8 inhibitor IRS661 to validate if 
HCV stimulation goes through TLR7/8. In addition, chloroquine was used to validate the 
involvement of endosome processing. Results showed that around 50% of TNF-α 
production was inhibited by IRS661, and chloroquine completely abolished TNF-α 
production induced by HCV in macrophages (Figure 5A). To clarify the mechanism of 
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selective activation of macrophages by HCV, we examined the responsiveness of 
macrophages and monocytes to TLR7/8 and TLR3 agonists. Results showed that both 
macrophages and monocytes responded to Cl097 and poly I:C, but only macrophages 
produced TNF-α upon HCV stimulation (Figure 5B). Furthermore, both macrophages and 
monocytes respond to Sendai virus stimulation (Figure5C), it indicates that monocytes 
possess the capability to detect RNA viruses but still fail to respond to HCV stimulation. 
This suggests that differences in responsiveness of macrophages and monocytes to HCV 
might be due to mechanisms other than availability of RNA sensors.  
 
6. DC-SIGN expression and responsiveness to HCV 
 
One possible cause of the differences in responsiveness of macrophages and 
monocytes may be their ability to uptake a virus. Thus, we kept monocytes or 
macrophages in incubation with HCV for 4hrs. In order to measure those viruses actually 
entering cells, we used trypsin to remove virus binding on the surface. As shown in 
Figure 6, both macrophages and monocytes can bind HCV, however, HCV RNA 
becomes undetectable in monocytes after trypsin treatment. In contrast, although viral 
RNA was decreased in macrophages after trypsin treatment, most of the binding virus 
still remains (Figure 6A). These data indicate that HCVcc can bind to monocytes and 
macrophages, but internalization of a binding virus only occurs in macrophages, the virus 
binding to monocytes cannot enter cells.  
Viral entry usually was mediated by specific receptors; therefore, we examined 
CD81 and DC-SIGN, two known receptors on APCs that interact with HCV. Results 
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showed that all the subsets of APCs expressed CD81, explaining how all the subsets had 
the ability to capture HCV. However, DC-SIGN expression was only detected on 
macrophages, not on monocytes and DCs (Figure 6B). These data strongly suggest that 
DC-SIGN might be the receptor that mediated the internalization of the virus captured by 
macrophages. To validate the role of DC-SIGN in uptake of HCV, we used a neutralizing 
antibody that can block the interaction of DC-SIGN with its ligand or HCV Envelope 
protein. Macrophages were incubated with HCV in the absence or presence of DC-SIGN-
blocking antibody or isotype control. Compared to isotype and nontreated macrophages, 
TNF-α production by macrophages with DC-SIGN blocking was significantly decreased 
(up to 85%) (Figure 6C). This provides solid evidence for DC-SIGN-mediated 
internalization in macrophages. 
 
7. Difference in responsiveness of DC-SIGN expressing cells to HCV 
DC-SIGN was found on macrophages and residential DCs in tissue (Soilleux, 
Morris et al. 2002). As we have shown above, DC-SIGN plays a crucial role in the 
detection of HCV. This raises an interesting question as to whether DC-SIGN expressing 
DCs respond to HCV stimulation. Monocyte-differentiated DCs (MDDC), on which cells 
DC-SIGN was identified, express abundant DC-SIGN, if DC-SIGN is the determinant of 
HCV detection, MDDC is expected to be responsive to HCV stimulation. We stimulated 
MDDCs with HCVcc and measured TNF-α production after 24hrs as above. Surprisingly, 
MDDCs responded to TLR7/8 agonist but did not show responsiveness to HCVcc 
stimulation as expected (Figure 7B), in spite of the fact that DC-SIGN expression on 
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MDDCs was much higher than on macrophages (Figure 7A). To investigate if MDDCs 
have the capability to detect RNA virus and produce TNF-α, we used the Sendai virus, 
which is known as a strong activator of TLR7/8 in DCs. Unlike HCVcc, Sendai virus 
induced a large amount of TNF-α production by both macrophages and MDDCs (Figure 
7B). This indicates that the non-responsiveness of MDDCs to HCVcc is not due to 
functional deficiency in the detection of RNA virus. HCV might escape detection by 
MDDCs. 
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Discussion 
 
This study demonstrates that macrophages directly sense HCV and initiate an 
inflammatory response. Significantly, although HCV RNA triggers TNF-α production by 
PBMCs like other viral RNA, the mechanism of HCV detection appears to be different 
from that of other viruses like human immunodeficiency virus (HIV), influenza virus 
(flu), or Sendai virus (SV) that can directly stimulate different subsets of APCs. Here we 
have shown that HCV can be detected directly only by macrophages but not peripheral 
DCs and monocytes, in spite of all subsets expressing HCV receptor CD81 and capturing 
HCV. The unresponsiveness of monocytes to HCVcc may be due to the failure of the 
internalization of a binding virus.  
It is very interesting that monocytes gain the ability to uptake and respond to 
HCV during the differentiation into macrophages (Figure 2B). The DC-SIGN has been 
reported to interact with HCV glycoproteins and was proposed as a receptor on APCs that 
mediate the uptake of HCV by DCs (Feng, Wang et al. 2004). Our results showed that 
DC-SIGNs selectively express on macrophages but not monocytes, pDCs, and mDCs, 
which is consistent with the selective responsiveness of macrophages to HCV. This 
strongly suggests that DC-SIGN-mediated endocytosis might be the mechanism of HCV 
detection by macrophages. Validation by DC-SIGN-blocking antibodies reveals that DC-
SIGNs play a critical role in detection of HCV by macrophages. Peripheral DCs do not 
express DC-SIGN (Sun, Fernandez et al. 2009), but DC-SIGN is still detectable on a few 
of the peripheral myeloid cells and dermal DCs (Geijtenbeek, Krooshoop et al. 2000, 
Gringhuis, van der Vlist et al. 2010). However, DC-SIGN expression does not endow 
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DCs with a great ability to detect HCV. Although MDDCs are also differentiated from 
monocytes and express much higher DC-SIGN than macrophages, our results showed 
that MDDCs did not respond to HCVcc stimulation. This suggests that macrophages and 
DCs may capture and process a virus in different ways. It is controversial that DC-SIGN 
expression permits HCV entry into DCs (Ludwig, Lekkerkerker et al. 2004, Lai, Sun et 
al. 2006). Viruses can be detected by PRRs or escape detection, the key that determines 
detection or evasion might be the endosome-lysosome pathway it is involved in. It was 
reported that cells expressing DC-SIGN can capture HCV viral-like particles (VLP) and 
lead to internalization. However, viral protein is targeted to the early endosome but not 
the later endosome or lysosome in DC-SIGN-expressing THP-1 or MDDCs. In contrast 
to DCs, HCV VLP was targeted to lysosome in other DC-SIGN-expressing cell lines 
(Ludwig, Lekkerkerker et al. 2004). It was known that uncoating of HCV requires 
acidification (Coller, Berger et al. 2009). Thus, a virus might escape detection of PRRs 
and “hide” within DCs as it was targeted to a non-lysosomal compartment. The same 
mechanism was observed for HIV, and it was utilized by the virus for viral dissemination 
(Geijtenbeek and van Kooyk 2003). Moreover, another possible explanation for the 
unresponsiveness of MDDCs to HCV is that DC-SIGN expression does not permit HCV 
entry into MDDCs. It was reported that cell-surface expression of DC-SIGN failed to 
confer permissiveness to HCV pseudo-type infection (Hsu, Zhang et al. 2003). 
Furthermore, no HCV RNA was detected in MDDCs from persistently infected 
chimpanzees (Larsson, Babcock et al. 2004).  
Here we have shown that activation of macrophages by HCV results in production 
of inflammatory cytokines, including TNF-α, IL-6, IL-8, and IL1b that have been 
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reported to be up-regulated in HCV-infected individuals. During chronic HCV infection, 
resident tissue macrophages like Kupffer cells (KCs) that express DC-SIGN (Schwartz, 
Alvarez et al. 2002) could be activated by HCV and become a major source of 
inflammatory cytokines, leading to recruitment of immune cells and liver damage. 
Cytokines such as TNF-α and IL-8 have been known as key factors that cause liver 
cirrhosis and resistance to interferon treatment. It has been shown that KCs activation and 
TNF-α induction are associated with hepatocellular apoptosis, inflammation, and the 
fibrosis process (Liu, Tao et al. 2010). It was reported that levels of IL-8 were 
significantly elevated in HCV-infected patients compared to levels in healthy subjects, 
and more importantly, levels of IL-8 were also significantly higher in patients who did 
not respond to IFN therapy than in patients who did respond to therapy (Polyak, Khabar 
et al. 2001). This suggests that HCV-induced cytokines by macrophages may be involved 
in antiviral resistance, persistence, and pathogenesis.  
Type I interferon is considered as a key factor for the innate immune system to 
control HCV infection, as it has shown great antiviral activity and also has promising 
clinical records in hepatitis C therapy. The capability of immune cells to restrict viral 
replication also most likely depends on interferon induction (Knapp, Yee et al. 2003, 
Saito, Owen et al. 2008, Takahashi, Asabe et al. 2010). However, although HCV could be 
recognized by macrophages resulting in immune activation and production of 
inflammatory cytokines, up-regulation of interferon expression and related genes were 
not observed in activated macrophages, and cell-culture supernatant exhibits negligible 
antiviral activity (Figure 3, Figure 4). Lack of interferon induction upon HCV stimulation 
is not due to the inhibitory effect of HCV protein or the inability of HCV to stimulate 
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macrophages, since TNF-α expression was induced. HCV triggers TLR7/8 receptors 
(Figure 1D and Figure 2), which have alternative signaling in macrophages and are 
characterized by a lack of IFN-beta induction (Schroder, Spille et al. 2007). Interestingly, 
HCV seems to selectively stimulate macrophages that do not produce IFN when TLR7/8 
is triggered, and it escapes detection by APCs which do produce type I IFN when TLR7/8 
is engaged. This may partially explain the failure of the innate immunity to control viral 
infection and impaired adaptive immunity in vivo. Whereas type I IFN and IFN-induced 
genes are detected in the liver early during infection regardless of its outcome (Bigger, 
Brasky et al. 2001, Su, Pezacki et al. 2002, Thimme, Bukh et al. 2002, Wieland and 
Chisari 2005). This suggests that the existence of another mechanism besides direct 
detection of HCV by macrophages. The cellular source of IFN in vivo is not certain. 
Although hepatocytes have been proposed, it is controversial whether HCV infection 
induces IFN in hepatocytes (Mihm, Frese et al. 2004, Cheng, Zhong et al. 2006, Kanda, 
Steele et al. 2007). The absence of intrahepatic IFN induction was also observed in vivo. 
Another possibility is that liver pDCs sense HCV-infected hepatocytes and produce IFNs 
(Takahashi, Asabe et al. 2010). However, induction of Type I IFN and related genes in 
the liver does not determine the outcome of infection (Su, Pezacki et al. 2002), and most 
infected individuals develop chronic infection, implying that the contribution of antiviral 
immunity mediated by pDCs is limited. Many factors may cause failure of innate 
immunity: limited interaction of pDCs and HCV-infected hepatocytes, blockade of TLR 
and IFN pathways by HCV proteins, a tolerogenic environment formed by activated 
Kupffer cells, or infected hepatocytes. 
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Materials and methods 
 
Cell lines 
Hepatoma cell huh7.5 (kind gift from by Dr. Charles Rice, Rockefeller University) and 
Hepatoma cell Huh7.5-20 producing JFH1 HCV (Kindly provide by Dr. T. Jake Liang, 
National Institutes of Health) were cultured in DMEM-based complete growth medium.  
Isolation monocytes, DCs and Preparation of macrophages, MDDCs 
Human peripheral blood mononuclear cells (PBMCs) were isolated from leukapheresis 
following ficoll procedure. Monocytes were isolated from PBMCs by using human 
monocytes enrichment kit (STEMCELL Technologies Inc, Canada), purity was 
confirmed by staining with CD14-PB. Pan-DCs were isolated from PBMCs by using 
Human pan-DC pre-enrichment kit (STEMCELL Technologies Inc, Canada). To prepare 
macrophages, purified monocytes were cultured in X-vivo 15 medium (lonzabio, USA) 
for 6 days in the presence of granulocyte-macrophage colony-stimulating factor (GM-
CSF, 50ng/ml, R&D systems, USA). To obtain MDDCs, purified monocytes were 
cultured in X-vivo 15 medium supplemented with GM-CSF (50ng/ml) and IL-4 
(20ng/ml). 
Viral production, quantification and concentration 
Cell line huh7.5-20 stably producing HCV was cultured in DMEM-based complete 
growth medium for 4 days, supernatant was harvested and filtered by 0.45um filter 
(sarstedt, Germany). Viral RNA was extracted from supernatant by using QIAamp Viral 
RNA Mini Kit (QIAGEN, USA) and cDNAs were synthesized by SuperScript® VILO™ 
cDNA Synthesis Kit (invitrogen, USA). Real time PCR was performed to quantify viral 
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RNA by using LightCycler® 480 Probes Master (ROCHE, USA), forward primer 5’-
CGGGAGAGCCATAGTGG-3’, reverse primer 5‘-AGTACCACAAGGCCTTT-3’, 
probe 5'- /56-FAM/CTGCGGAACCGGTGAGTACAC/3IABlkFC (IDT, USA). RNA 
standard was prepared by in vitro transcription using MEGAscript® T7 Kit (ambion, 
USA), quantity of RNA was determined by OD260 and RNA copies were calculated by 
formula from QIAGEN. Culture medium of huh7.5 and huh7.5-20 were concentrated by 
passing Amicon ultra-15 centrifugal filter-100 (Millipore, USA), filters were sterilized 
with 70% alcohol before using.  
Cell stimulation, cytokines production and gene expression 
In vitro differentiated macrophages and isolated monocytes, pan-DCs were cultured in X-
vivo 15 medium at 96 wells plate. Cells were incubated with HCVcc for 24hrs, 
supernatants were harvested after centrifuge, cytokine production was measured by 
Human TNF alpha ELISA Ready-SET, and inflammatory cytokines were measured by 
Cytometric Bead Array (CBA) by using Human Inflammatory Cytokine Kit 
(bdbiosciences, USA). TLR7/8 agonist cl097 and TLR3 agonist poly I:C were obtained 
from invivogen. For measurement of IFN and IFN-stimulated genes (IFIT1, OAS1 and 
IAS15), cells were stimulated with HCVcc for indicated time and washed with PBS, total 
RNA was extracted by RNeasy Mini Kit (QIAGEN, USA) and DNase treatment was 
performed using DNA-free kit (ambion, USA), cDNA synthesis and real-time PCR were 
performed as described above.  
Flow Cytometry 
Expression of CD81 and DC-SIGN were measured by flow Cytometry. PBMCs were 
stained with live/dead stain (invitrogen, USA), anti-CD14-Pacific blue, anti-Linage-
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Alexa700 (CD3, CD19, CD16), anti-HLA-DR-APC-cy7, anti-CD11c-APC, anti-CD123-
FITC, anti-CD81-PE (BDbioscience, USA) or anti-DC-SIGN-PE (R&D systems, USA) 
and analyzed on an LSR II (BD bioscience). CD81 and DC-SIGN expression were 
measured on monocytes (CD14+), mDCs (Lin-CD14-HLA-DR+CD11c+CD123-/dim) and 
pDCs (Lin-CD14-HLA-DR+CD11c-CD123+). Macrophages and MDDCs were also 
stained with anti-CD81-PE or anti-DC-SIGN-PE to detect CD81 and DC-SIGN 
expression. 
Uptake of HCVcc by macrophages 
Macrophages and monocytes were incubated with HCVcc for 4hrs at 37°C, cells were 
intensively washed with PBS and then incubated with or without trypsin at 37°C (water 
bath) for 5mins. After intensive wash, cells were used for RNA extraction and 
quantification by real-time PCR. 
Statistical analysis 
p-values were determined using two way paired student’s t tests. p–values less than 0.05 
were considered statistically significant. 
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Figure 1: Macrophages sense HCV.  
(A) 2x104 PBMCs were incubated with HCVcc, DOTAP or HCV RNA-DOTAP complex 
for 24 hours. (B, C, D) Purified pan-DCs, monocytes and monocytes-derived 
macrophages were incubated with HCVcc or TLR7/8 agonist Cl097 for 24 hours. TNF-α 
production were measured by ELISA. “NS”, non-stimulated cells. 
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Figure 2: Dose-dependent activation and Inflammatory cytokines induction by 
HCVcc stimulation.  
(A) 105 MDMs were stimulated with different ratio of HCVcc for 24h. (B) 105 MDMs or 
monocytes (n=20) were stimulated with HCVcc at ratio 20 for 24h. TNF-α production 
were measured by ELISA. (C) Inflammatory cytokines production by HCVcc stimulated 
MDMs were measured by CBA. NS indicates non-stimulated cells 
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Figure 3: Expression of interferon and interferon-stimulated genes in macrophages 
upon HCV stimulation.  
(A) 105 MDMs were stimulated with HCVcc, LPS or Cl097 for 3h, TNF-α and IFNb1 
expression were measured by real time PCR. (B) 105 MDMs were stimulated with 
HCVcc or LPS for 16h, interferon-stimulated genes (IFIT1, OAS1, ISG15) and TNF-α 
were measured by real time PCR, results shown as fold change to gene expression in non-
stimulated cells. “NS”, non-stimulated cells. 
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Figure 4: Antiviral activity and responsiveness to HCV.  
Macrophages (A) or monocytes (B) were stimulated with cl097 for 3h. TNF and IFNb1 
expression were measured by real time PCR. Supernatants from non-stimulated or cl097 
stimulated macrophages (C) or monocytes (D) were added to HCV infected huh7.5, cells 
were washed and fresh medium were replaced, viral RNA in the supernatants were 
measured by real time PCR. macrophages (E) or monocytes (F) were incubated with 
HCVcc for 24h, TNF-α production in the supernatants were measured by ELISA. NS 
indicates non-stimulated cells 
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Figure 5: Pathway involved in HCV recognition.  
(A) Macrophages were stimulated with HCVcc in the presence of TLR7/8 inhibitor 
IRS661 or chloroquine for 24h. (B) MDMs and monocytes were stimulated with HCVcc, 
medium (huh7.5 culture), cl097 (1ug/ml), polyI:C (30ug/ml) or LPS (1ng/ml) for 24h. 
TNF-α production were measured by ELISA. (C) 105 of macrophages and monocytes 
were stimulated with Sendai virus or CL097 for 24h. TNF-α production was measured by 
ELISA. “NS”, non-stimulated cells 
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Figure 6: DC-SIGN mediated uptake of HCV.  
(A) Macrophage and monocytes were incubated with or without (N) HCV at 37 °C for 
4h, cells were washed and treated with trypsin at 37 °C for 5min. After extensive wash, 
total RNA are extracted and viral RNA are measured by real-time PCR. Results were 
represented as percentage of viral RNA in cells without trypsin treatment. Viral RNA was 
normalized to GAPDH. (B) Macrophages or PBMCs were stained with isotype (open), 
anti-CD81 or anti-DC-SIGN (filled), CD81 and DC-SIGN expression on macrophages, 
monocytes, mDC and pDC by flow Cytometry. (C) Macrophages were incubated with 
medium, isotype control and DC-SIGN blocking antibody for 1 hour, then cells were 
stimulated with HCV for 24hrs, TNF-α production was measured by ELISA. Results 
were shown as concentration and percentage of TNF-α induced by HCV alone. 
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Figure 7: Responsiveness of macrophages and MDDCs to HCV.  
Monocytes were cultured in the presence of GMCSF or GMCSF/IL4 respectively to 
generate macrophages and mDDCs, cells were harvested at day 6 and used for staining or 
stimulation. (A) DC-SIGN expression on macrophages and MDDCs were measured by 
flow cytometry. Cells were stained with isotype (open) or anti-DC-SIGN (filled) (B) 105 
of macrophages and MDDCs were stimulated with HCV or CL097, or Sendai virus or 
CL097 for 24h. TNF-α production were measured by ELISA. NS indicates non-
stimulated cells 
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1. Summary of findings 
In this study, we revealed that HCV RNA possesses the capability to initiate 
innate immune responses via triggering TLR7/8, and that the HCV genome contains GU-
rich sequences that can be recognized by TLR7/8. Three sequences in the HCV genome 
were identified as ligands of TLR7/8.  
Stimulation with HCV-derived ssRNAs resulted in the maturation of pDC and the 
production of type I Interferon, HCV ssRNA also induced the production of 
inflammatory cytokines and chemokines by different APCs. Cytokines produced by 
stimulated monocytes and pDCs significantly inhibited HCV production (2 to 3 log 
decrease). Viral production could be restored by antibody against interferon-alpha/beta 
R2 (IFNAR2). Cytokines produced by activated mDCs barely affected viral production, 
which might be due to the absence of IFN signaling. Furthermore, HCV-RNA-mediated 
cytokines decreased CD81 expression on huh7.5. This down-regulation was not induced 
by type I IFN. 
Moreover, we demonstrated that not only HCV RNA but also HCV virions can be 
detected by some APCs. However, among different APCs that we tested (monocytes, 
pan-DCs, macrophages, and MDDCs), only macrophages were able to respond to 
HCVcc. Incubation of macrophages with HCVcc resulted in production of inflammatory 
cytokines including TNF-α, IL-1β, IL-6, and IL-8. Interestingly, stimulation of 
macrophages with HCVcc did not lead to induction of IFN and IFN-stimulated genes 
(IFIT1, OAS1, and ISG15). This phenomenon is very similar to TLR7/8 signaling in 
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macrophages. Involvement of TLR7/8 in HCV detection by macrophages was validated 
by using IRS661, a specific inhibitor of TLR7/8 (Barrat, Meeker et al. 2005). 
We also showed that monocytes and macrophages captured HCV, but 
internalization occurred only in macrophages. Viral RNA was not detectable in 
monocytes after trypsin treatment. Although CD81 was broadly expressed on different 
peripheral APCs, DC-SIGN was detected only on macrophages. This strongly suggested 
that DC-SIGN plays an important role in HCV detection. The anti-DC-SIGN antibody, 
which blocks the interaction of DC-SIGN with HCV glycoprotein, validated the 
hypothesis that DC-SIGN is involved in HCV detection by macrophages. However, 
monocyte-differentiated DCs, which express very high levels of DC-SIGN, were 
unresponsive to HCV stimulation, suggesting that DC-SIGN expression is not the only 
determinant of the responsiveness to HCV. 
 
2. Immunogenicity of HCV 
Knowledge about the immunogenicity of HCV remains elusive. Although 
immune activation was observed in HCV-infected individuals (Bigger, Brasky et al. 
2001), it has been very difficult to prove that HCV is immunogenic and able to activate 
APCs in vitro (Liang, Russell et al. 2009, Zhang, Guo et al. 2009, Takahashi, Asabe et al. 
2010). The involvement of HCV proteins in both immune activation and 
immunosuppression was reported (Yao, Ray et al. 2001, Dolganiuc, Oak et al. 2004). It 
was shown that HCV proteins, core and NS3, trigger TLR2 to induce inflammatory 
activation (Dolganiuc, Oak et al. 2004), and TLR1 and TLR6 are involved in the process 
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of recognition of HCV Core and NS3 protein (Chang, Dolganiuc et al. 2007). In another 
study, TLR2 was shown to sense the hepatitis C virus core protein but not infectious 
virons (Hoffmann, Zeisel et al. 2009), suggesting that the intact structure of virons 
prevent recognition of core by TLR2. Core and NS3 proteins released from apoptotic 
hepatocytes may induce immune activation; HCV Core protein is detectable in the 
plasma of HCV-infected patients (Orito, Mizokami et al. 1996, Tanaka, Kiyosawa et al. 
1996). On the contrary, both core and NS3 also exhibit strong inhibitory effects on the 
production of TLR-mediated cytokines (Tu, Pierce et al. 2010, Abe, Kaname et al. 2007). 
It is still unclear how HCV proteins contribute to activation of the innate immune system 
during HCV infection. 
As an RNA virus, HCV RNA is an important PAMP that can be recognized by 
RNA sensors to initiate an innate immune response. Indeed, as we showed in Figure 1A 
in chapter 2, HCV RNA was capable to induce inflammatory cytokines production by 
PBMCs. Two RNA sensors, RIG-I and TLR7, have been proposed as the receptors that 
are responsible for detection of HCV RNA. Saito et al. reported that single-strand RNA 
of HCV triggers RIG-I to induce an IFN-dependent immune defense in hepatocytes, and 
a similar immune activation was observed in vivo with hydrodynamic RNA transfection 
in their study (Saito, Owen et al. 2008). However, in contrast to TLR7 and 8, RIG-I is 
expressed in the cytoplasmic compartments and not in the endosomes where HCV 
particles are likely to reside upon their uptake by APCs. Thus, TLR7/8 are most likely 
responsible for HCV detection. Moreover, the HCV genome contains GU-rich sequences, 
the essential motif for TLR7/8 recognition (Heil, Hemmi et al. 2004). Here, we proved 
that HCV RNA could trigger TLR7/8 in APCs (Figure 1D, Figure 2, chapter2). HCV-
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derived GU-rich sequences were functional as TLR7/8 agonists to induce DC maturation 
and cytokine production (Figure 3, Figure 4). Interestingly, not all the GU-rich sequences 
we selected in the HCV genome can trigger TLR7/8. Actually, 6 out of 9 selected 
sequences failed to induce TNF-α production, despite we selected all sequences with the 
same criterions and similar GU/U density, which suggests that the presence of GU in the 
RNA sequence is not sufficient to be a ligand of TLR7/8, certain motif in GU-rich 
sequences is required for recognition by TLR7/8. However, GU is an indispensable 
character for RNA that triggers TLR7/8. Our results showed that U-to-A replacement of 
GU motifs completely abolished the stimulatory effects of those identified ssRNAs. 
Although many studies have tried to identify the precise motif for TLR7/8 recognition, 
they represent only part of the motifs that trigger TLR7/8 (Heil, Hemmi et al. 2004, 
Hornung, Guenthner-Biller et al. 2005, Forsbach, Nemorin et al. 2008). Anyhow, our 
study reveals that HCV RNA contains GU-rich sequences that trigger TLR7/8. Those 
GU-rich sequences endow HCV RNA with the capability to induce innate immune 
activation. 
 
3. TLR7 and innate immunity against HCV infection 
TLR7 agonists, which strongly induce type I interferon in pDCs, have been 
considered as potential candidates for HCV therapy. Several clinical trials have shown 
significant induction of type I interferon and viremia suppression by TLR7 agonists 
(Horsmans, Berg et al. 2005, Pockros, Guyader et al. 2007, Bergmann, de Bruijne et al. 
2011). TLR7-mediated antiviral response was also observed in human hepatocyte lines 
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(Lee, Wu et al. 2006). All those studies demonstrated that TLR7 may play an important 
role in innate immunity against HCV infection. Viral RNA can be detected by TLR7 
(Lund, Alexopoulou et al. 2004). It has been reported that pDCs could be activated by 
HCV-infected hepatocytes via TLR7 (Takahashi, Asabe et al. 2010). However, the ability 
of HCV RNA to trigger TLR7 and induce an immune response is still not well addressed. 
GU-rich sequences were identified as an essential motif to be recognized by TLR7 (Heil, 
Hemmi et al. 2004, Hornung, Guenthner-Biller et al. 2005). Based on previous findings, 
we selected GU-rich sequences from the HCV genome, and three sequences were 
identified as ligands of TLR7/8 (Figures 1 and 2, chapter 2). Our results showed that 
HCV ssRNA is an agonist of TLR7/8, specifically triggering TLR7 or TLR8 receptors, 
induction of DC maturation and type I interferon production, and induction of cytokine 
production profile in peripheral APCs (Figures 3 and 4, chapter 2). Moreover, similar to 
another TLR7 agonist, HCV ssRNA exhibited remarkable antiviral activity when it 
stimulates peripheral APCs. Indeed, HCV-ssRNA-induced cytokines significantly 
inhibited HCV production (Figure 5, chapter 2). This suggests HCV is able to induce 
antiviral response via TLR7/8 and restrict viral infection if APCs detect viral RNA and 
initiate immune response properly. However, as we showed, HCV particles escape 
triggering of DCs and monocytes, which can mount type I IFN and exhibit optimal anti-
viral responses upon TLR7/8 activation. HCV Particles are able to activate macrophages 
through TLR7/8; however, these cells do not mount an anti-viral response against HCV. 
TLR7 plays an important role in anti-HCV defense in hepatocytes. However, this 
is not optimal as it was previously shown that decreased TLR7 expression and function in 
HCV-infected hepatocytes is a mechanism to prevent efficient innate immune responses 
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to HCV, thus highlighting the different layers of HCV escape mechanisms. A further 
level of escape mechanisms may arise from the fact that HCV Particles are able to 
activate macrophages, however these cells do not mount an anti-viral response against 
HCV when TLR7/8 are triggered. HCV also escape triggering of DCs and monocytes, 
two cellular subsets that can compensate and mount optimal responses. 
 
4. Induction of innate immune response and inflammation in HCV infection 
Immune response induced by HCV infection is characterized as rapid innate 
immune response and delayed adaptive immune response (Dustin and Rice 2007), 
regardless of the outcome of the disease progression. Innate immune activation was 
observed at an early stage after HCV infection in chimpanzees (Bigger, Brasky et al. 
2001). Inflammatory cytokines also have been shown to be up-regulated in chronically 
HCV-infected individuals (Polyak, Khabar et al. 2001). This implies that the innate viral 
infection rapidly induce immune response. However, it has been difficult to clarify the 
mechanisms of immune activation induced by HCV infection, as immune activation in 
infected hepatocytes is obscure and DCs exhibit unresponsiveness to HCV in vitro 
(Bigger, Guerra et al. 2004, Wieland, Makowska et al. 2013). The sources of 
inflammation during HCV infection are not well defined. HCV can infect hepatocytes 
(Cormier, Tsamis et al. 2004), or it can be captured by liver sinusoidal endothelial cells 
(LSECs) through L-sign (Gardner, Durso et al. 2003, Cormier, Durso et al. 2004) or by 
resident DCs that express DC-SIGN (Ludwig, Lekkerkerker et al. 2004) and 
macrophages (Figure 6, chapter 3). HCV components (proteins Core and NS3, viral 
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RNA) were reported as possessing the capability to initiate innate immune activation 
(Dolganiuc, Oak et al. 2004, Zhang, Guo et al. 2009). As we demonstrated, HCV RNA 
can be detected by APCs and lead to production of inflammatory cytokines and 
chemokines (Figures 1, 3, chapter 2). The immune activation is mediated by TLR7/8 
(Figure 2, chapter2). It also has been shown that HCV-infected hepatocytes activate 
pDCs through cell–cell contact, resulting in the production of type I IFN (Takahashi, 
Asabe et al. 2010).  
Persistent HCV infections are typically associated with inflammatory response, 
which is related to HCV infection driving fibrogenesis, with increased deposition of 
extracellular matrix proteins leading to fibrotic scarring and ultimately cirrhosis (Tarao, 
Ohkawa et al. 2013). Activation of hepatic stellate cells (HSCs) is known to be important 
in this process and may be cytokine-driven, but the specific mechanisms are not very 
clear (Giannelli and Antonaci 2005). The sensing of HCV infection by the innate immune 
system likely contributes to these processes. As we showed, monocytes, mDCs and pDCs 
that were stimulated with HCV RNA produce abundant cytokines, such as TNF-α, IL-6, 
IL-12, IL-1b, and IL-10, and chemokines CXCL9 and CXCL10 (Figure 3, chapter 2). 
Immune activation induced by HCV RNA leads to production of inflammatory cytokines 
and chemokines that might promote the formation of an inflammatory environment in the 
liver, which are crucial for recruiting immune cells and activation of HSCs. 
In this study, we demonstrated for the first time that HCV can be detected directly 
by APCs, but only macrophages ,not peripheral DCs, monocytes, and MDDCs, respond 
to HCV stimulation and produce inflammatory cytokines (Figures 1 and 2, chapter 3). 
Macrophages detect HCV particles directly and produce TNF-α, IL-1β, IL-6, and IL-8 
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(Figure 2, chapter3). This suggests that HCV-induced activation of macrophages in the 
liver (Kupffer cells) may contribute to the formation of the inflammatory environment, 
activation of HSCs, and further fibrosis. The release of chemokines (i.e., IL-8) is 
followed by recruitment of inflammatory cells, which further leads to tissue damage, 
leading to repeated cycles of inflammation and damage. TNF-α leads to altered 
expression of cell adhesion molecules on sinusoidal endothelial allowing the recruitment 
and sinusoidal transmigration of inflammatory cells (Bissell, Wang et al. 1995, Neubauer, 
Wilfling et al. 2000). Activated Kupffer cells and recruited inflammatory cells establish a 
special cytokine environment, which is of crucial importance in activation of HSCs 
(Grappone, Pinzani et al. 1999, Luo, Tang et al. 2005). The activated HSCs lose their 
ability to store fat and retinoids and produce cytokines, leading to an autocrine effect of 
the activation and proliferation of portal fibroblasts and myofibroblasts (Salmi, Adams et 
al. 1998). Thus, activation of macrophages induced by HCV might contribute to 
inflammation and promote disease progression.  
 
5. Detection of HCV by antigen-presenting cells 
Although the immunogenicity of HCV components (RNA or proteins) have been 
shown (Dolganiuc, Oak et al. 2004, Zhang, Guo et al. 2009), DCs appear “silent” when 
they encounter HCV (Liang, Russell et al. 2009, Zhang, Guo et al. 2009, Takahashi, 
Asabe et al. 2010). Many efforts have been made to prove the immunogenicity of HCV 
particles, but the only common element in those studies is the unresponsiveness of DCs to 
HCV stimulation. Neither DC maturation nor induction of cytokines was observed 
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(Shiina and Rehermann 2008, Liang, Russell et al. 2009, Zhang, Guo et al. 2009, 
Takahashi, Asabe et al. 2010). In concordance with previous findings, our results 
demonstrated that DCs, as well as monocytes, fail to respond to HCV stimulation 
(Figures 1B, C). HCV seems to utilize unique strategies to escape from DC detection, 
whereas other RNA viruses such as the influenza virus, Sendai virus, and HIV induce 
strong immune responses to DCs in vitro (Lee, Lund et al. 2007, Mandl, Barry et al. 
2008).  
The mechanisms of DC unresponsiveness to HCV are not known, and the causes 
that endow HCV with an “undetectable” characteristic still remain unidentified. Two 
possible mechanisms have been proposed and broadly studied: inhibitory effects of HCV 
proteins and inefficient uptake of HCV. HCV proteins such as core, NS3, and NS5A 
exhibited strong inhibitory effects on signaling of PRRs (Abe, Kaname et al. 2007, Tu, 
Pierce et al. 2010). Those proteins were thought to be the cause of the tolerance of DCs to 
viral stimulation. HCV particles were reported to have the same inhibitory effects on 
particular TLRs, such as TLR9, the mechanism is unclear (Shiina and Rehermann 2008). 
However, the inhibitory effects of HCV particles do not depend on expression of viral 
proteins since the inhibition does not require viral infection or entry of DCs (Shiina and 
Rehermann 2008). Moreover, HCV particles have no effect on cytokine induction and 
DC maturation induced by RNA virus or LPS (Shiina and Rehermann 2008), suggesting 
that HCV does not alter the capability of DCs to respond to virus or microbe stimulation. 
Similarly, the responsiveness of macrophages to HCV we observed in this study also 
implies that HCV virons do not generally shut down the function of PRRs. HCV still can 
be detected and induce an immune response.  
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The HCV uptake capability of DCs remains controversial. The internalization of 
HCV-like particles by DCs (Ludwig, Lekkerkerker et al. 2004, Barth, Ulsenheimer et al. 
2005) and the absence of HCV in DCs from HCV-infected patients (Rollier, Drexhage et 
al. 2003, Longman, Talal et al. 2004) were both reported. Recently, it has been shown 
that PBMCs (Cormier, Tsamis et al. 2004) or peripheral DCs (Kaimori, Kanto et al. 
2004) are certainly not susceptible to HCV infection. HCV particles in PBMCs from 
patients are predominantly carried on the surface of cells (Natarajan, Kottilil et al. 2010). 
Thus, many studies, together with our results, allow us to speculate that the 
unresponsiveness of DCs to HCV might be due to the incapability of viral uptake.  
The process of HCV uptake by APCs is still unclear. Although peripheral DCs 
express very low levels of receptors that are essential for HCV infection on hepatocytes 
(such as CD81, SRBI, and CLDN1), HCV does not infect DCs (Kaimori, Kanto et al. 
2004, Marukian, Jones et al. 2008). DC-SIGN, a Lectin that has been shown to interact 
with HCV glycoprotein, was proposed as the receptor for HCV uptake by DCs 
(Pohlmann, Zhang et al. 2003, Ludwig, Lekkerkerker et al. 2004). DC-SIGN has been 
found on resident DCs and macrophages in the lymph nodes and the liver (Schwartz, 
Alvarez et al. 2002, Lai, Sun et al. 2006, Gringhuis, van der Vlist et al. 2010). However, 
as we and others (Mengshol, Golden-Mason et al. 2009, Sun, Fernandez et al. 2009) have 
shown, DC-SIGN was not detected on peripheral DCs (Figure 6B, chapter 3), whereas it 
expressed on macrophages (Figure 6B, chapter 3). Interestingly, macrophages—the only 
subset of APCs expressing DC-SIGN among APCs we tested—were the only subset that 
responded to HCV stimulation (Figure 1D, chapter 3). This suggests that DC-SIGN is 
involved in HCV detection by macrophages. Indeed, the blockade of DC-SIGN inhibited 
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TNF-α production induced by HCV (Figure 6C, chapter 3). Thus, DC-SIGN does play a 
critical role in HCV detection. To investigate whether DC-SIGN is sufficient to endow 
APCs with the capability to sense HCV, we used monocyte-derived DCs (MDDCs), on 
which DC-SIGN was initially identified. DC-SIGN is highly expressed on MDDC 
(Figure 7A). As we showed (Figure 7B, chapter3), MDDCs unexpectedly did not respond 
to HCV stimulation, although those MDDCs exhibited strong responsiveness to other 
RNA viruses (Figure 7B, chapter 3). The mechanism that causes differences in 
responsiveness of macrophages and MDDCs to HCV is unknown. Both macrophages and 
MDDCs are derived from monocytes; the difference is that IL-4 is required for MDDCs 
differentiation. IL-4 induces a high level of DC-SIGN expression on DCs (Relloso, Puig-
Kroger et al. 2002), however, it also may alter other properties of DCs (Montaner, da 
Silva et al. 1999). It was reported that myeloid DCs became susceptible to pseudo-type 
HCV with GM-CSF pretreatment, but GM-CSF-induced susceptibility was impaired in 
the presence of additional IL-4 (Kaimori, Kanto et al. 2004). It has also been shown that 
IL-4 could alter the endocytic activity in macrophages, leading to targeting of internalized 
particles to a non-lysosomal compartment (Montaner, da Silva et al. 1999), which was 
proposed as a viral strategy to escape detection by PPRs (Ludwig, Lekkerkerker et al. 
2004).  
 
6. Interferon and control of HCV infection 
Type I interferon has been considered a key factor that mediates immune defense 
to control HCV infection. It has exhibited great antiviral activity and has good clinical 
127 
 
records in hepatitis C therapy (Dammacco, Tucci et al. 2010). Many studies have shown 
that establishment of immune defense in hepatoma cell lines or cytokine-mediated 
suppression of HCV replication totally depends on IFN induction. In accordance with 
previous studies, our results also showed that HCV RNA has the capability to induce 
cytokines that strongly inhibit HCV replication in an IFN-dependent manner (Figure 5, 
chapter2). mDCs (Figure 5,chapter 2) and macrophages (Figure 5, chapter 3) did not 
produce IFN upon HCV RNA stimulation and failed to restrict HCV replication.  
Type I interferon and IFN-stimulated genes were rapidly induced in HCV-
infected subjects, and the IFN response was correlated with the magnitude and duration 
of HCV infection. The source of interferon in vivo is still not well defined. We have 
shown that HCV RNA can induce IFN-β in pDCs or monocytes resulting in inhibition of 
HCV replication. Therefore, HCV RNA is able to induce optimal anti-viral immune 
responses by monocytes and pDCs; however, these cells are indeed compromised in their 
recognition of HCV particles (Figure 1, chapter 3). The mechanisms of unresponsiveness 
are still unknown. Our study demonstrated that macrophages possess the capacity to 
sense HCV (Figure 2, chapter 3). However, the immune response induced by HCV in 
macrophages lacks IFN production and IFN signaling (Figure 4, chapter 3), which are key 
mediators of viral inhibition. pDCs were proposed as the source of interferon. Recently, it 
has been shown that pDCs could be activated by HCV-infected hepatocytes via TLR7/8, 
resulting in production of type I interferon. Cell–cell contact is required in this process 
(Takahashi, Asabe et al. 2010). Infiltration of pDCs in patient liver tissues was observed, 
however, IFN-signaling was absent in intrahepatic pDCs. Also, IFN-stimulated gene 
(ISG-15)-expressing cells did not co-localize with pDCs (Lau, Fish et al. 2008). This 
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implies that pDCs may be not the major source of interferon in the liver of hepatitis C 
patients. In accordance with these observations, our results showed that HCV complete 
particles, but not viral RNA, do not induce activation of IFN-α/β producing cells 
(monocytes/pDCs), likely due to a blockage in the virus entry process, which might 
represent an escape mechanism of HCV from detection by innate immunity.  
Intrahepatic interferon signaling was observed and associated with HCV viremia, 
regardless of the outcome of the disease progression (Su, Pezacki et al. 2002, Thimme, 
Bukh et al. 2002). This suggests that HCV induces type I interferon in vivo, but the 
infection is not controlled by it. Instead, up-regulation of IFN-stimulated genes has been 
defined as a predictor of non-responsiveness to interferon therapy (Sarasin-Filipowicz, 
Oakeley et al. 2008). The mechanisms of failure of intrahepatic interferon to control HCV 
infection are still mysterious. It is known that an innate immune response is impaired in 
the presence of HCV proteins (Abe, Kaname et al. 2007, Tu, Pierce et al. 2010). 
However, inhibitory effects of HCV proteins cannot explain the failure of infection 
control by interferon, since intrahepatic IFN-stimulated genes are detected (Sarasin-
Filipowicz, Oakeley et al. 2008). Persistent HCV infections are typically associated with 
an inflammatory response that is characterized as an infiltration of immune cells and the 
formation of a cytokine environment in the liver (Bigger, Guerra et al. 2004, Blackard, 
Komurian-Pradel et al. 2006, Lau, Fish et al. 2008), which might alter the antiviral 
activity of interferon induced by HCV infection. It was reported that IL-8 inhibits the 
antiviral action of interferon (Khabar, Al-Zoghaibi et al. 1997). The mechanism is still 
unclear. Our results showed that HCV could activate macrophages and induce abundant 
IL-8 (Figure 2, chapter3). The largest population of resident macrophages (Kupffer cells) 
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is in the liver. Those macrophages could be activated by HCV and produce IL-8, which 
might compromise an IFN-mediated innate defense. Indeed, up-regulation of IL-8 was 
found in chronically HCV-infected individuals, and elevated levels of IL-8 in serum were 
associated with resistance to interferon therapy (Polyak, Khabar et al. 2001). 
In conclusion, this study demonstrated that HCV RNA encodes for GU-rich 
sequences, which stimulate the production of inflammatory cytokines and chemokines by 
antigen presenting cells, upon triggering through TLR7 and TLR8. However, in contrast 
to pDCs, mDCs, monocytes and mDDCs, only macrophages can be stimulated by the 
complete HCV particles in a way that depends on endocytosis and partially involves 
TLR7 and TLR8, this activation is not optimal and does not mediate anti-viral responses 
due to lack of Type I interferon. This leads to the escape of HCV from the anti-
viralresponse mediated by APCs. Our results help in understanding the mechanisms of an 
effective innate immune response to HCV, which is useful to the development of an anti-
HCV vaccine and therapeutic interventions targeting TLR7, TLR8 and APCs to 
potentiate them for optimal antiviral response. 
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Perspectives 
 
Our results demonstrate that in vitro differentiated Macrophages are able to detect 
HCV via TLR7/8; DC-SIGN is involved in this process. To understand the mechanism of 
HCV detection by macrophages and its contribution to pathogenesis of HCV infection, 
several questions remain to be answered. 
1. Response or evasion 
As we described above, macrophages are able to detect HCV and produce 
inflammatory cytokines, peripheral DCs and monocytes do not respond to HCV due to 
the obstacle of HCV uptake which likely caused by lack of DC-SIGN expression. It was 
reported that DC-SIGN mediates efficient HCV uptake (Ludwig, Lekkerkerker et al. 
2004). Moreover, DC-SIGN is also detectable on tissue DCs and macrophages (Jameson, 
Baribaud et al. 2002, Soilleux, Morris et al. 2002), suggesting the possibility of HCV 
detection by DCs. However, as we showed, DC-SIGN expressing MDDCs do not 
respond to HCV stimulation. The differences between macrophages and MDDCs in HCV 
internalization may be the key to uncover the mechanism of HCV detection. Ludwig IS et 
al revealed that DC-SIGN mediated internalization is cell type dependent, the captured 
HCV can be targeted differently to intracellular compartments in different cells. 
Internalized HCV virus-like particles were targeted to non-lysosomal compartments 
within immature DCs, where they are protected from lysosomal degradation (Ludwig, 
Lekkerkerker et al. 2004). This may explain the un-responsiveness of MDDCs to HCV, 
as recognition of viral RNA by TLR7 takes place in lysosome (Lund, Alexopoulou et al. 
2004). HCV may target DC-SIGN to escape immune surveillance. To verify this 
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hypothesis, localization of internalized HCV in macrophages and MDDCs need to be 
determined. Furthermore, we need to investigate the HCV responsiveness of tissue DCs 
and Kupffer cells.  
2. Inflammation and resistance 
Most interesting finding in this study is that HCV induce production of inflammatory 
cytokines but not interferon in macrophages. Since anti-HCV activity of interferon is 
dose dependent (Lam, Neumann et al. 1997), as the only APC we identified that respond 
to HCV stimulation, lack of interferon production may compromise the innate immune 
response against HCV infection. Furthermore, macrophages produce high level of IL-8 
upon HCV stimulation (Chapter 3, Figure 2), a chemokine strongly inhibits interferon 
antiviral activity (Khabar, Al-Zoghaibi et al. 1997). It has been shown that elevated levels 
of interleukin-8 in serum are associated with HCV infection and resistance to interferon 
therapy; it implies that macrophages activated by HCV may contribute to pathogenesis of 
HCV infection. To determine the role of macrophages plays in HCV infection, we need 
to investigate the relationship of macrophage activation, inflammation and viral load. 
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